{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T22:25:51Z","timestamp":1792016751605,"version":"4.4.0"},"reference-count":270,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,5,19]],"date-time":"2024-05-19T00:00:00Z","timestamp":1716076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,19]],"date-time":"2024-05-19T00:00:00Z","timestamp":1716076800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100019345","name":"King Salman Center for Disability Research","doi-asserted-by":"publisher","award":["KSRG-2023-242"],"award-info":[{"award-number":["KSRG-2023-242"]}],"id":[{"id":"10.13039\/501100019345","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch. Pharm. Res."],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s12272-024-01499-w","type":"journal-article","created":{"date-parts":[[2024,5,19]],"date-time":"2024-05-19T19:01:27Z","timestamp":1716145287000},"page":"571-595","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Exploring molecular mechanisms, therapeutic strategies, and clinical manifestations of Huntington\u2019s disease"],"prefix":"10.1007","volume":"47","author":[{"given":"Alaa","family":"Shafie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amal Adnan","family":"Ashour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saleha","family":"Anwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farah","family":"Anjum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3663-4940","authenticated-orcid":false,"given":"Md. Imtaiyaz","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,19]]},"reference":[{"issue":"4","key":"1499_CR1","doi-asserted-by":"publisher","first-page":"409","DOI":"10.4331\/wjbc.v5.i4.409","volume":"5","author":"N Adachi","year":"2014","unstructured":"Adachi N, Numakawa T, Richards M, Nakajima S, Kunugi H (2014) New insight in expression, transport, and secretion of brain-derived neurotrophic factor: implications in brain-related diseases. World J Biol Chem 5(4):409\u2013428. https:\/\/doi.org\/10.4331\/wjbc.v5.i4.409","journal-title":"World J Biol Chem"},{"issue":"4","key":"1499_CR2","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1128\/MMBR.67.4.657-685.2003","volume":"67","author":"N Agrawal","year":"2003","unstructured":"Agrawal N, Dasaradhi PVN, Mohmmed A, Malhotra P, Bhatnagar RK, Mukherjee SK (2003) RNA interference: biology, mechanism, and applications. Microbiol Mol Biol Rev 67(4):657\u2013685. https:\/\/doi.org\/10.1128\/MMBR.67.4.657-685.2003","journal-title":"Microbiol Mol Biol Rev"},{"key":"1499_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-016-0128-x","author":"C Agust\u00edn-Pav\u00f3n","year":"2016","unstructured":"Agust\u00edn-Pav\u00f3n C, Mielcarek M, Garriga-Canut M, Isalan M (2016) Deimmunization for gene therapy: host matching of synthetic zinc finger constructs enables long-term mutant Huntingtin repression in mice. Mole Neurodegener. https:\/\/doi.org\/10.1186\/s13024-016-0128-x","journal-title":"Mole Neurodegener"},{"issue":"3","key":"1499_CR4","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1007\/s12035-022-03150-5","volume":"60","author":"SS Alkanli","year":"2023","unstructured":"Alkanli SS, Alkanli N, Ay A, Albeniz I (2023) CRISPR\/Cas9 mediated therapeutic approach in Huntington\u2019s disease. Mol Neurobiol 60(3):1486\u20131498. https:\/\/doi.org\/10.1007\/s12035-022-03150-5","journal-title":"Mol Neurobiol"},{"issue":"1","key":"1499_CR5","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1176\/appi.psy.47.1.70","volume":"47","author":"M Alpay","year":"2006","unstructured":"Alpay M, Koroshetz WJ (2006) Quetiapine in the treatment of behavioral disturbances in patients with Huntington\u2019s disease. Psychosomatics 47(1):70\u201372. https:\/\/doi.org\/10.1176\/appi.psy.47.1.70","journal-title":"Psychosomatics"},{"key":"1499_CR6","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.mito.2023.05.007","volume":"71","author":"T Alqahtani","year":"2023","unstructured":"Alqahtani T, Deore SL, Kide AA, Shende BA, Sharma R, Chakole RD, Nemade LS, Kale NK, Borah S, Deokar SS (2023) Mitochondrial dysfunction and oxidative stress in Alzheimer\u2019s disease, and Parkinson\u2019s disease, Huntington\u2019s disease and amyotrophic lateral sclerosis-an updated review. Mitochondrion Jul 71:83\u201392. https:\/\/doi.org\/10.1016\/j.mito.2023.05.007","journal-title":"Mitochondrion Jul"},{"issue":"6653","key":"1499_CR7","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1038\/39885","volume":"389","author":"CA Altar","year":"1997","unstructured":"Altar CA, Cai N, Bliven T, Juhasz M, Conner JM, Acheson AL, Lindsay RM, Wiegand SJ (1997) Anterograde transport of brain-derived neurotrophic factor and its role in the brain. Nature 389(6653):856\u2013860. https:\/\/doi.org\/10.1038\/39885","journal-title":"Nature"},{"issue":"1","key":"1499_CR8","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/BF02257483","volume":"20","author":"CM Ambrose","year":"1994","unstructured":"Ambrose CM, Duyao MP, Barnes G, Bates GP, Lin CS, Srinidhi J, Baxendale S, Hummerich H, Lehrach H, Altherr M, Wasmuth J, Buckler A, Church D, Housman D, Berks M, Micklem G, Durbin R, Dodge A, Read A, MacDonald ME (1994) Structure and expression of the Huntington\u2019s disease gene: evidence against simple inactivation due to an expanded CAG repeat. Somatic Cell Genetics 20(1):27\u201338. https:\/\/doi.org\/10.1007\/BF02257483","journal-title":"Somatic Cell Genetics"},{"issue":"12","key":"1499_CR9","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.3390\/metabo12121225","volume":"12","author":"KE Anderson","year":"2022","unstructured":"Anderson KE, Stevenson M, Varghese R, Hebron ML, Koppel E, McCartin M, Kuprewicz R, Matar S, Ferrante D, Moussa C (2022) Alteration of autophagy and glial activity in nilotinib-treated Huntington\u2019s disease patients. Metabolites 12(12):1225. https:\/\/doi.org\/10.3390\/metabo12121225","journal-title":"Metabolites"},{"key":"1499_CR10","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.28484","author":"R Andhale","year":"2022","unstructured":"Andhale R, Shrivastava D (2022) Huntington\u2019s disease: a clinical review. Cureus. https:\/\/doi.org\/10.7759\/cureus.28484","journal-title":"Cureus"},{"issue":"6","key":"1499_CR11","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1212\/WNL.0b013e318263c443","volume":"79","author":"MJ Armstrong","year":"2012","unstructured":"Armstrong MJ, Miyasaki JM, American Academy of Neurology (2012) Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the guideline development subcommittee of the American Academy of Neurology: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 79(6):597\u2013603. https:\/\/doi.org\/10.1212\/WNL.0b013e318263c443","journal-title":"Neurology"},{"key":"1499_CR12","doi-asserted-by":"publisher","first-page":"710","DOI":"10.3389\/fneur.2019.00710","volume":"10","author":"A-C Bachoud-L\u00e9vi","year":"2019","unstructured":"Bachoud-L\u00e9vi A-C, Ferreira J, Massart R, Youssov K, Rosser A, Busse M, Craufurd D, Reilmann R, De Michele G, Rae D (2019) International guidelines for the treatment of Huntington\u2019s disease. Front Neurol 10:710. https:\/\/doi.org\/10.3389\/fneur.2019.00710","journal-title":"Front Neurol"},{"key":"1499_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2015.5","author":"S Badadhe","year":"2024","unstructured":"Badadhe S, Bhosale V, Kulkarni P, Gangurde H (2024) Huntington disease: brief overview. Innov J Med Healthcare Res. https:\/\/doi.org\/10.1038\/nrdp.2015.5","journal-title":"Innov J Med Healthcare Res"},{"issue":"4","key":"1499_CR14","doi-asserted-by":"publisher","first-page":"331","DOI":"10.2217\/nmt-2016-0008","volume":"6","author":"SS Baig","year":"2016","unstructured":"Baig SS, Strong M, Quarrell OW (2016) The global prevalence of Huntington\u2019s disease: a systematic review and discussion. Neurodegener Dis Manag 6(4):331\u2013343. https:\/\/doi.org\/10.2217\/nmt-2016-0008","journal-title":"Neurodegener Dis Manag"},{"key":"1499_CR15","doi-asserted-by":"publisher","first-page":"4250","DOI":"10.1523\/JNEUROSCI.3920-03.2004","volume":"24","author":"ZC Baquet","year":"2004","unstructured":"Baquet ZC, Gorski JA, Jones KR (2004) Early striatal dendrite deficits followed by neuron loss with advanced age in the absence of anterograde cortical brain-derived neurotrophic factor. J Neurosci 24:4250\u20134258. https:\/\/doi.org\/10.1523\/JNEUROSCI.3920-03.2004","journal-title":"J Neurosci"},{"key":"1499_CR16","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1212\/wnl.38.1.84","volume":"38","author":"A Barr","year":"1988","unstructured":"Barr A, Fischer J, Roller W, Spunt A, Singhal A (1988) Serum haloperidol concentration and choreiform movements in Huntington\u2019s disease. Neurology 38:84\u201384. https:\/\/doi.org\/10.1212\/wnl.38.1.84","journal-title":"Neurology"},{"key":"1499_CR17","doi-asserted-by":"publisher","first-page":"NS20210019","DOI":"10.1042\/NS20210019","volume":"5","author":"OJ Bartley","year":"2021","unstructured":"Bartley OJ, Lelos MJ, Gray WP, Rosser AE (2021) Do foetal transplant studies continue to be justified in Huntington\u2019s disease? Neuronal Signaling 5:NS20210019. https:\/\/doi.org\/10.1042\/NS20210019","journal-title":"Neuronal Signaling"},{"key":"1499_CR18","doi-asserted-by":"publisher","first-page":"awae105","DOI":"10.1093\/brain\/awae105","volume":"8","author":"J Belgrad","year":"2024","unstructured":"Belgrad J, Khvorova A (2024) More than 185 CAG repeats: a point of no return in Huntington\u2019s disease biology. Brain 8:awae105. https:\/\/doi.org\/10.1093\/brain\/awae105","journal-title":"Brain"},{"key":"1499_CR19","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1002\/1531-8257(199905)14:3<398::aid-mds1003>3.0.co;2-f","volume":"14","author":"A Berardelli","year":"1999","unstructured":"Berardelli A, Noth J, Thompson PD, Bollen EL, Curr\u00e0 A, Deuschl G, Gert Van Dijk J, T\u00f6pper R, Schwarz M, Roos RA (1999) Pathophysiology of chorea and bradykinesia in Huntington\u2019s disease. Mov Disord 14:398\u2013403. https:\/\/doi.org\/10.1002\/1531-8257(199905)14:3%3c398::aid-mds1003%3e3.0.co;2-f","journal-title":"Mov Disord"},{"key":"1499_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2022.110296","author":"AA Bhat","year":"2023","unstructured":"Bhat AA, Gupta G, Afzal O, Kazmi I, Al-Abbasi FA, Altamimi ASA, Almalki WH, Alzarea SI, Singh SK, Dua K (2023) Neuropharmacological effect of risperidone: from chemistry to medicine. Chem Biol Interactions. https:\/\/doi.org\/10.1016\/j.cbi.2022.110296","journal-title":"Chem Biol Interactions"},{"issue":"12","key":"1499_CR21","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.2174\/1381612826666200113162641","volume":"26","author":"O Binvignat","year":"2020","unstructured":"Binvignat O, Olloquequi J (2020) Excitotoxicity as a target against neurodegenerative processes. Curr Pharm Des 26(12):1251\u20131262. https:\/\/doi.org\/10.2174\/1381612826666200113162641","journal-title":"Curr Pharm Des"},{"key":"1499_CR22","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1097\/00004714-200104000-00023","volume":"21","author":"G Bogelman","year":"2001","unstructured":"Bogelman G, Hirschmann S, Modai I (2001) Olanzapine and Huntington\u2019s disease. J Clin Psychopharmacol 21:245\u2013246. https:\/\/doi.org\/10.1097\/00004714-200104000-00023","journal-title":"J Clin Psychopharmacol"},{"key":"1499_CR23","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1007\/s00415-002-0741-1","volume":"249","author":"RM Bonelli","year":"2002","unstructured":"Bonelli RM, Niederwieser G (2002) Quetiapine in Huntington\u2019s disease: a first case report. J Neurol 249:1114\u20131115. https:\/\/doi.org\/10.1007\/s00415-002-0741-1","journal-title":"J Neurol"},{"key":"1499_CR24","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1097\/00002826-200209000-00007","volume":"25","author":"RM Bonelli","year":"2002","unstructured":"Bonelli RM, Mahnert FA, Niederwieser G (2002) Olanzapine for Huntington\u2019s disease: an open label study. Clin Neuropharmacol 25:263\u2013265. https:\/\/doi.org\/10.1097\/00002826-200209000-00007","journal-title":"Clin Neuropharmacol"},{"key":"1499_CR25","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1212\/wnl.44.5.821","volume":"44","author":"U Bonuccelli","year":"1994","unstructured":"Bonuccelli U, Ceravolo R, Maremmani C, Nuti A, Rossi G, Muratorio A (1994) Clozapine in Huntington\u2019s chorea. Neurology 44:821\u2013821. https:\/\/doi.org\/10.1212\/wnl.44.5.821","journal-title":"Neurology"},{"key":"1499_CR26","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1345\/aph.17216","volume":"33","author":"CS Brown","year":"1999","unstructured":"Brown CS, Markowitz JS, Moore TR, Parker NG (1999) Atypical antipsychotics: part II adverse effects, drug interactions, and costs. Ann Pharmacother 33:210\u2013217. https:\/\/doi.org\/10.1345\/aph.17216","journal-title":"Ann Pharmacother"},{"key":"1499_CR27","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1023\/b:nere.0000014824.04728.dd","volume":"29","author":"SE Browne","year":"2004","unstructured":"Browne SE, Beal MF (2004) The energetics of Huntington\u2019s disease. Neurochem Res 29:531\u2013546. https:\/\/doi.org\/10.1023\/b:nere.0000014824.04728.dd","journal-title":"Neurochem Res"},{"key":"1499_CR28","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1002\/mds.22376","volume":"24","author":"L Brusa","year":"2009","unstructured":"Brusa L, Orlacchio A, Moschella V, Iani C, Bernardi G, Mercuri NB (2009) Treatment of the symptoms of Huntington\u2019s disease: preliminary results comparing aripiprazole and tetrabenazine. Mov Disord 24:126\u2013129. https:\/\/doi.org\/10.1002\/mds.22376","journal-title":"Mov Disord"},{"key":"1499_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/currents.RRN1260","author":"J-M Burgunder","year":"2011","unstructured":"Burgunder J-M, Guttman M, Perlman S, Goodman N, Van Kammen DP, Goodman L (2011) An international survey-based algorithm for the pharmacologic treatment of chorea in Huntington\u2019s disease. PLoS Curr. https:\/\/doi.org\/10.1371\/currents.RRN1260","journal-title":"PLoS Curr"},{"key":"1499_CR301","doi-asserted-by":"publisher","unstructured":"Byun S, Lee M,  Kim M (2022) Gene therapy for Huntington\u2019s disease: the final strategy for a cure? Journal of Movement Disorders 15(1):15. https:\/\/doi.org\/10.14802\/jmd.21006","DOI":"10.14802\/jmd.21006"},{"key":"1499_CR30","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1176\/ajp.136.3.317","volume":"136","author":"ED Caine","year":"1979","unstructured":"Caine ED, Polinsky RJ, Kartzinel R, Ebert MH (1979) The trial use of clozapine for abnormal involuntary movement disorders. Am J Psychiatry 136:317\u2013320. https:\/\/doi.org\/10.1176\/ajp.136.3.317","journal-title":"Am J Psychiatry"},{"issue":"3","key":"1499_CR31","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.3469","volume":"14","author":"LX Cao","year":"2024","unstructured":"Cao LX, Yin JH, Du G, Yang Q, Huang Y (2024) Identifying and verifying Huntington\u2019s disease subtypes: clinical features, neuroimaging, and cytokine changes. Brain Behav 14(3):e3469. https:\/\/doi.org\/10.1002\/brb3.3469","journal-title":"Brain Behav"},{"issue":"4","key":"1499_CR32","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1523\/JNEUROSCI.1865-20.2020","volume":"41","author":"NS Caron","year":"2021","unstructured":"Caron NS, Banos R, Yanick C, Aly AE, Byrne LM, Smith ED, Xie Y, Smith SEP, Potluri N, Findlay Black H, Casal L, Ko S, Cheung D, Kim H, Seong IS, Wild EJ, Song J-J, Hayden MR, Southwell AL (2021) Mutant huntingtin is cleared from the brain via active mechanisms in Huntington disease. J Neurosci 41(4):780\u2013796. https:\/\/doi.org\/10.1523\/JNEUROSCI.1865-20.2020","journal-title":"J Neurosci"},{"key":"1499_CR33","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/s0166-2236(00)01721-5","volume":"24","author":"E Cattaneo","year":"2001","unstructured":"Cattaneo E, Rigamonti D, Goffredo D, Zuccato C, Squitieri F, Sipione S (2001) Loss of normal huntingtin function: new developments in Huntington\u2019s disease research. Trends Neurosci 24:182\u2013188. https:\/\/doi.org\/10.1016\/s0166-2236(00)01721-5","journal-title":"Trends Neurosci"},{"key":"1499_CR34","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1038\/nrn1806","volume":"6","author":"E Cattaneo","year":"2005","unstructured":"Cattaneo E, Zuccato C, Tartari M (2005) Normal huntingtin function: an alternative approach to Huntington\u2019s disease. Nat Rev Neurosci 6:919\u2013930. https:\/\/doi.org\/10.1038\/nrn1806","journal-title":"Nat Rev Neurosci"},{"key":"1499_CR35","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.bbrc.2007.05.093","volume":"359","author":"C-M Chen","year":"2007","unstructured":"Chen C-M, Wu Y-R, Cheng M-L, Liu J-L, Lee Y-M, Lee P-W, Soong B-W, Chiu DT-Y (2007) Increased oxidative damage and mitochondrial abnormalities in the peripheral blood of Huntington\u2019s disease patients. Biochem Biophys Res Commun 359:335\u2013340. https:\/\/doi.org\/10.1016\/j.bbrc.2007.05.093","journal-title":"Biochem Biophys Res Commun"},{"key":"1499_CR36","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1016\/j.clinthera.2012.06.010","volume":"34","author":"JJ Chen","year":"2012","unstructured":"Chen JJ, Ondo WG, Dashtipour K, Swope DM (2012) Tetrabenazine for the treatment of hyperkinetic movement disorders: a review of the literature. Clin Ther 34:1487\u20131504. https:\/\/doi.org\/10.1016\/j.clinthera.2012.06.010","journal-title":"Clin Ther"},{"key":"1499_CR37","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1002\/ajmg.b.30501","volume":"144","author":"A Ciammola","year":"2007","unstructured":"Ciammola A, Sassone J, Cannella M, Calza S, Poletti B, Frati L, Squitieri F, Silani V (2007) Low brain-derived neurotrophic factor (BDNF) levels in serum of Huntington\u2019s disease patients. Am J Med Genet B Neuropsychiatr Genet 144:574\u2013577. https:\/\/doi.org\/10.1002\/ajmg.b.30501","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"1499_CR38","doi-asserted-by":"publisher","DOI":"10.2147\/ndt.s12160236","author":"A Ciammola","year":"2009","unstructured":"Ciammola A, Sassone J, Colciago C, Mencacci NE, Poletti B, Ciarmiello A, Squitieri F, Silani V (2009) Aripiprazole in the treatment of Huntington\u2019s disease: a case series. Neuropsychiatric Dis Treat. https:\/\/doi.org\/10.2147\/ndt.s12160236","journal-title":"Neuropsychiatric Dis Treat"},{"key":"1499_CR39","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/s0165-0173(00)00039-4","volume":"34","author":"F Cicchetti","year":"2000","unstructured":"Cicchetti F, Prensa LA, Wu Y, Parent A (2000) Chemical anatomy of striatal interneurons in normal individuals and in patients with Huntington\u2019s disease. Brain Res Rev 34:80\u2013101. https:\/\/doi.org\/10.1016\/s0165-0173(00)00039-4","journal-title":"Brain Res Rev"},{"key":"1499_CR40","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.13030","volume":"71","author":"L Citrome","year":"2017","unstructured":"Citrome L (2017) Deutetrabenazine for tardive dyskinesia: A systematic review of the efficacy and safety profile for this newly approved novel medication\u2014What is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract 71:e13030. https:\/\/doi.org\/10.1111\/ijcp.13030","journal-title":"Int J Clin Pract"},{"issue":"5","key":"1499_CR41","doi-asserted-by":"publisher","first-page":"207","DOI":"10.9740\/mhc.2023.10.207","volume":"13","author":"DO Claassen","year":"2023","unstructured":"Claassen DO, Ayyagari R, Garc\u00eda-Horton V, Zhang S, Leo S (2023) Predictors of persistence and adherence to deutetrabenazine among patients with Huntington disease or tardive dyskinesia. Ment Health Clin 13(5):207\u2013216. https:\/\/doi.org\/10.9740\/mhc.2023.10.207","journal-title":"Ment Health Clin"},{"key":"1499_CR42","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s40265-016-0670-4","volume":"77","author":"EM Coppen","year":"2017","unstructured":"Coppen EM, Roos RA (2017) Current pharmacological approaches to reduce chorea in Huntington\u2019s disease. Drugs 77:29\u201346. https:\/\/doi.org\/10.1007\/s40265-016-0670-4","journal-title":"Drugs"},{"key":"1499_CR43","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.nbd.2018.08.010","volume":"122","author":"KR Croce","year":"2019","unstructured":"Croce KR, Yamamoto A (2019) A role for autophagy in Huntington\u2019s disease. Neurobiol Dis 122:16\u201322. https:\/\/doi.org\/10.1016\/j.nbd.2018.08.010","journal-title":"Neurobiol Dis"},{"key":"1499_CR44","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1159\/000516767","volume":"55","author":"V Crowell","year":"2021","unstructured":"Crowell V, Houghton R, Tomar A, Fernandes T, Squitieri F (2021) Modeling manifest Huntington\u2019s disease prevalence using diagnosed incidence and survival time. Neuroepidemiology 55:361\u2013368. https:\/\/doi.org\/10.1159\/000516767","journal-title":"Neuroepidemiology"},{"key":"1499_CR45","doi-asserted-by":"publisher","first-page":"571","DOI":"10.3390\/antiox12030571","volume":"12","author":"F D\u2019Egidio","year":"2023","unstructured":"D\u2019Egidio F, Castelli V, Cimini A, D\u2019angelo M (2023) Cell rearrangement and oxidant\/antioxidant imbalance in huntington\u2019s disease. Antioxidants 12:571. https:\/\/doi.org\/10.3390\/antiox12030571","journal-title":"Antioxidants"},{"key":"1499_CR46","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3389\/fnins.2018.00075","volume":"12","author":"M Dabrowska","year":"2018","unstructured":"Dabrowska M, Juzwa W, Krzyzosiak WJ, Olejniczak M (2018) Precise excision of the CAG tract from the huntingtin gene by Cas9 nickases. Front Neurosci 12:75. https:\/\/doi.org\/10.3389\/fnins.2018.00075","journal-title":"Front Neurosci"},{"key":"1499_CR47","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.mito.2023.03.001","volume":"70","author":"Y Dai","year":"2023","unstructured":"Dai Y, Wang H, Lian A, Li J, Zhao G, Hu S, Li B (2023) A comprehensive perspective of Huntington\u2019s disease and mitochondrial dysfunction. Mitochondrion 70:8\u201319. https:\/\/doi.org\/10.1016\/j.mito.2023.03.001","journal-title":"Mitochondrion"},{"key":"1499_CR48","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1097\/00004714-199902000-00020","volume":"19","author":"C Dallocchio","year":"1999","unstructured":"Dallocchio C, Buffa C, Tinelli C, Mazzarello P (1999) Effectiveness of risperidone in Huntington chorea patients. J Clin Psychopharmacol 19:101\u2013103. https:\/\/doi.org\/10.1097\/00004714-199902000-00020","journal-title":"J Clin Psychopharmacol"},{"key":"1499_CR49","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1007\/s13311-020-00891-w","volume":"17","author":"D Dash","year":"2020","unstructured":"Dash D, Mestre TA (2020) Therapeutic update on Huntington\u2019s disease: symptomatic treatments and emerging disease-modifying therapies. Neurotherapeutics 17:1645\u20131659. https:\/\/doi.org\/10.1007\/s13311-020-00891-w","journal-title":"Neurotherapeutics"},{"issue":"4","key":"1499_CR50","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1097\/01.JAA.0000735740.95438.60","volume":"34","author":"C De La","year":"2021","unstructured":"De La C, Hwang J (2021) On the hunt for a cure: a guide to Huntington disease. JAAPA 34(4):26\u201331","journal-title":"JAAPA"},{"issue":"48","key":"1499_CR51","doi-asserted-by":"publisher","first-page":"18540","DOI":"10.1074\/jbc.RA118.004621","volume":"293","author":"SM De Guire","year":"2018","unstructured":"De Guire SM, Ruggeri FS, Fares MB, Chiki A, Cendrowska U, Dietler G, Lashuel HA (2018) N-terminal Huntingtin (Htt) phosphorylation is a molecular switch regulating Htt aggregation, helical conformation, internalization, and nuclear targeting. J Biol Chem 293(48):18540\u201318558. https:\/\/doi.org\/10.1074\/jbc.RA118.004621","journal-title":"J Biol Chem"},{"key":"1499_CR52","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1002\/mds.20235","volume":"19","author":"M De Tommaso","year":"2004","unstructured":"De Tommaso M, Specchio N, Sciruicchio V, Difruscolo O, Specchio LM (2004) Effects of rivastigmine on motor and cognitive impairment in Huntington\u2019s disease. Mov Disord 19:1516\u20131518. https:\/\/doi.org\/10.1002\/mds.20235","journal-title":"Mov Disord"},{"key":"1499_CR53","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/S1474-4422(11)70233-2","volume":"10","author":"JG De Yebenes","year":"2011","unstructured":"De Yebenes JG, Landwehrmeyer B, Squitieri F, Reilmann R, Rosser A, Barker RA, Saft C, Magnet MK, Sword A, Rembratt \u00c5 (2011) Pridopidine for the treatment of motor function in patients with Huntington\u2019s disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Neurol 10:1049\u20131057. https:\/\/doi.org\/10.1016\/S1474-4422(11)70233-2","journal-title":"Lancet Neurol"},{"key":"1499_CR54","doi-asserted-by":"publisher","first-page":"103","DOI":"10.3390\/brainsci14010103","volume":"14","author":"L Dellosso","year":"2024","unstructured":"Dellosso L, Bonelli C, Nardi B, Giovannoni F, Pronest\u00ec C, Cremone IM, Amatori G, Pini S, Carpita B (2024) Rethinking clozapine: lights and shadows of a revolutionary drug. Brain Sci 14:103. https:\/\/doi.org\/10.3390\/brainsci14010103","journal-title":"Brain Sci"},{"key":"1499_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2019.104569","volume":"132","author":"HL Denis","year":"2019","unstructured":"Denis HL, David LS, Cicchetti F (2019) Antibody-based therapies for Huntington\u2019s disease: current status and future directions. Neurobiol Dis 132:104569. https:\/\/doi.org\/10.1016\/j.nbd.2019.104569","journal-title":"Neurobiol Dis"},{"issue":"105642","key":"1499_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2022.105642","volume":"120","author":"SJ Devadiga","year":"2022","unstructured":"Devadiga SJ, Bharate SS (2022) Recent developments in the management of Huntington\u2019s disease. Bioorg Chem 120(105642):105642. https:\/\/doi.org\/10.1016\/j.bioorg.2022.105642","journal-title":"Bioorg Chem"},{"key":"1499_CR57","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/0896-6273(95)90346-1","volume":"14","author":"M Difiglia","year":"1995","unstructured":"Difiglia M, Sapp E, Chase K, Schwarz C, Meloni A, Young C, Martin E, Vonsattel J-P, Carraway R, Reeves SA (1995) Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons. Neuron 14:1075\u20131081. https:\/\/doi.org\/10.1016\/0896-6273(95)90346-1","journal-title":"Neuron"},{"key":"1499_CR58","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1136\/jnnp.67.1.123","volume":"67","author":"HC Dipple","year":"1999","unstructured":"Dipple HC (1999) The use of olanzapine for movement disorder in Huntington\u2019s disease: a first case report. J Neurol Neurosurg Psychiatry 67:123\u2013124. https:\/\/doi.org\/10.1136\/jnnp.67.1.123","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"1499_CR59","doi-asserted-by":"publisher","first-page":"175","DOI":"10.3233\/JHD-200445","volume":"10","author":"J Donaldson","year":"2021","unstructured":"Donaldson J, Powell S, Rickards N, Holmans P, Jones L (2021) What is the pathogenic CAG expansion length in Huntington\u2019s disease? J Huntington\u2019s Dis 10(1):175\u2013202. https:\/\/doi.org\/10.3233\/JHD-200445","journal-title":"J Huntington\u2019s Dis"},{"key":"1499_CR60","doi-asserted-by":"publisher","first-page":"fcaa230","DOI":"10.1093\/braincomms\/fcaa230","volume":"3","author":"CJ Drew","year":"2021","unstructured":"Drew CJ, Sharouf F, Randell E, Brookes-Howell L, Smallman K, Sewell B, Burrell A, Kirby N, Mills L, Precious S (2021) Protocol for an open label: phase I trial within a cohort of foetal cell transplants in people with Huntington\u2019s disease. Brain Commun 3:fcaa230. https:\/\/doi.org\/10.1093\/braincomms\/fcaa230","journal-title":"Brain Commun"},{"key":"1499_CR61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10401230701844802","volume":"20","author":"K Duff","year":"2008","unstructured":"Duff K, Beglinger LJ, O\u2019rourke ME, Nopoulos P, Paulson HL, Paulsen JS (2008) Risperidone and the treatment of psychiatric, motor, and cognitive symptoms in Huntington\u2019s disease. Ann Clin Psychiatry 20:1\u20133. https:\/\/doi.org\/10.1080\/10401230701844802","journal-title":"Ann Clin Psychiatry"},{"key":"1499_CR62","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1007\/s13311-012-0112-2","volume":"9","author":"ME Ehrlich","year":"2012","unstructured":"Ehrlich ME (2012) Huntington\u2019s disease and the striatal medium spiny neuron: cell-autonomous and non-cell-autonomous mechanisms of disease. Neurotherapeutics 9:270\u2013284. https:\/\/doi.org\/10.1007\/s13311-012-0112-2","journal-title":"Neurotherapeutics"},{"issue":"2","key":"1499_CR63","doi-asserted-by":"publisher","first-page":"129","DOI":"10.22034\/jcr.2023.362508.1194","volume":"5","author":"O Eje","year":"2023","unstructured":"Eje O, Ogbonna C, Onoyima C, Nduka F (2023) Huntington disease: mechanism of pathogenesis and recent developments in its therapeutic strategies: a review. J Chem Rev 5(2):129\u2013142. https:\/\/doi.org\/10.22034\/jcr.2023.362508.1194","journal-title":"J Chem Rev"},{"key":"1499_CR64","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.omtn.2019.07.009","volume":"17","author":"FK Ekman","year":"2019","unstructured":"Ekman FK, Ojala DS, Adil MM, Lopez PA, Schaffer DV, Gaj T (2019) CRISPR-Cas9-mediated genome editing increases lifespan and improves motor deficits in a Huntington\u2019s disease mouse model. Mol Ther Nucleic Acids 17:829\u2013839. https:\/\/doi.org\/10.1016\/j.omtn.2019.07.009","journal-title":"Mol Ther Nucleic Acids"},{"issue":"2","key":"1499_CR65","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1046\/j.1468-1331.2002.0354e.x","volume":"9","author":"AK Erdemoglu","year":"2002","unstructured":"Erdemoglu AK, Boratav C (2002) Risperidone in chorea and psychosis of Huntington\u2019s disease. European J Neurol 9(2):182\u2013183. https:\/\/doi.org\/10.1046\/j.1468-1331.2002.0354e.x","journal-title":"European J Neurol"},{"key":"1499_CR66","doi-asserted-by":"publisher","first-page":"1138712","DOI":"10.3389\/fnins.2023.1138712","volume":"17","author":"AM Estrada-S\u00e1nchez","year":"2023","unstructured":"Estrada-S\u00e1nchez AM, Rebec GV, Galvan L (2023) Editorial: new insight into Huntington\u2019s disease: from neuropathology to possible therapeutic targets. Front Neurosci 17:1138712. https:\/\/doi.org\/10.3389\/fnins.2023.1138712","journal-title":"Front Neurosci"},{"issue":"10","key":"1499_CR67","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1080\/14712598.2020.1792880","volume":"20","author":"MM Evers","year":"2020","unstructured":"Evers MM, Konstantinova P (2020) AAV5-miHTT gene therapy for Huntington disease: lowering both huntingtins. Expert Opin Biol Ther 20(10):1121\u20131124. https:\/\/doi.org\/10.1080\/14712598.2020.1792880","journal-title":"Expert Opin Biol Ther"},{"issue":"3","key":"1499_CR68","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1177\/0963689717753378","volume":"27","author":"H-C Fan","year":"2018","unstructured":"Fan H-C, Chi C-S, Lee Y-J, Tsai J-D, Lin S-Z, Harn H-J (2018) The role of gene editing in neurodegenerative diseases. Cell Transplant 27(3):364\u2013378. https:\/\/doi.org\/10.1177\/0963689717753378","journal-title":"Cell Transplant"},{"issue":"8","key":"1499_CR69","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1089\/ars.2019.8004","volume":"34","author":"L F\u00e3o","year":"2021","unstructured":"F\u00e3o L, Rego AC (2021) Mitochondrial and redox-based therapeutic strategies in Huntington\u2019s disease. Antioxid Redox Signal 34(8):650\u2013673. https:\/\/doi.org\/10.1089\/ars.2019.8004","journal-title":"Antioxid Redox Signal"},{"key":"1499_CR70","doi-asserted-by":"publisher","first-page":"117957352210925","DOI":"10.1177\/11795735221092517","volume":"14","author":"MW Ferguson","year":"2022","unstructured":"Ferguson MW, Kennedy CJ, Palpagama TH, Waldvogel HJ, Faull RLM, Kwakowsky A (2022) Current and possible future therapeutic options for Huntington\u2019s disease. J Central Nervous Syst Disease 14:11795735221092516. https:\/\/doi.org\/10.1177\/11795735221092517","journal-title":"J Central Nervous Syst Disease"},{"issue":"1","key":"1499_CR71","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1002\/1531-8257(200001)15:1<173::aid-mds1032>3.0.co;2-t","volume":"15","author":"HH Fernandez","year":"2000","unstructured":"Fernandez HH, Friedman JH, Grace J, Beason-Hazen S (2000) Donepezil for Huntington\u2019s disease. Mov Disord 15(1):173\u2013176. https:\/\/doi.org\/10.1002\/1531-8257(200001)15:1%3c173::aid-mds1032%3e3.0.co;2-t","journal-title":"Mov Disord"},{"key":"1499_CR72","doi-asserted-by":"publisher","first-page":"722","DOI":"10.2165\/00003495-199040050-00007","volume":"40","author":"A Fitton","year":"1990","unstructured":"Fitton A, Heel RC (1990) Clozapine: a review of its pharmacological properties, and therapeutic use in schizophrenia. Drugs 40:722\u2013747","journal-title":"Drugs"},{"issue":"1","key":"1499_CR73","doi-asserted-by":"publisher","first-page":"22137","DOI":"10.1038\/s41598-020-78790-5","volume":"10","author":"V Fodale","year":"2020","unstructured":"Fodale V, Pintauro R, Daldin M, Altobelli R, Spiezia MC, Bisbocci M, Macdonald D, Bresciani A (2020) Analysis of mutant and total huntingtin expression in Huntington\u2019s disease murine models. Sci Rep 10(1):22137. https:\/\/doi.org\/10.1038\/s41598-020-78790-5","journal-title":"Sci Rep"},{"issue":"1","key":"1499_CR74","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/1471-2377-9-62","volume":"9","author":"S Frank","year":"2009","unstructured":"Frank S (2009) Tetrabenazine as anti-chorea therapy in Huntington disease: an open-label continuation study. Huntington Study Group\/TETRA-HD Investigators. BMC Neurol 9(1):62. https:\/\/doi.org\/10.1186\/1471-2377-9-62","journal-title":"BMC Neurol"},{"key":"1499_CR75","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s13311-013-0244-z","volume":"11","author":"S Frank","year":"2014","unstructured":"Frank S (2014) Treatment of Huntington\u2019s disease. Neurotherapeutics 11:153\u2013160. https:\/\/doi.org\/10.1007\/s13311-013-0244-z","journal-title":"Neurotherapeutics"},{"issue":"1","key":"1499_CR76","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1001\/jama.2016.8655","volume":"316","author":"S Frank","year":"2016","unstructured":"Frank S, Testa CM, Stamler D, Kayson E, Davis C, Edmondson MC, Kinel S, Leavitt B, Oakes D, O\u2019Neill C, Vaughan C, Goldstein J, Herzog M, Snively V, Whaley J, Wong C, Suter G, Jankovic J, Christopher E (2016) Effect of deutetrabenazine on chorea among patients with Huntington disease: a randomized clinical trial: A randomized clinical trial. JAMA 316(1):40\u201350. https:\/\/doi.org\/10.1001\/jama.2016.8655","journal-title":"JAMA"},{"issue":"12","key":"1499_CR77","doi-asserted-by":"publisher","first-page":"4842","DOI":"10.1523\/jneurosci.22-12-04842.2002","volume":"22","author":"J Gafni","year":"2002","unstructured":"Gafni J, Ellerby LM (2002) Calpain activation in Huntington\u2019s disease. J Neurosci 22(12):4842\u20134849. https:\/\/doi.org\/10.1523\/jneurosci.22-12-04842.2002","journal-title":"J Neurosci"},{"issue":"11","key":"1499_CR78","doi-asserted-by":"publisher","first-page":"4010","DOI":"10.51891\/rease.v9i11.12684","volume":"9","author":"M Galindo","year":"2023","unstructured":"Galindo M, Da Silva GV, Lopes I, De Ara\u00fajo Ramos VE, De Oliveira T, Bueno G (2023) Unraveling huntington\u2019s disease: concepts, treatments and health policy challenges. Revista Ibero-Americana De Humanidades, Ci\u00eancias e Educa\u00e7\u00e3o 9(11):4010\u20134021. https:\/\/doi.org\/10.51891\/rease.v9i11.12684","journal-title":"Revista Ibero-Americana De Humanidades, Ci\u00eancias e Educa\u00e7\u00e3o"},{"key":"1499_CR79","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.neubiorev.2019.04.002","volume":"102","author":"CPC Galts","year":"2019","unstructured":"Galts CPC, Bettio LEB, Jewett DC, Yang CC, Brocardo PS, Rodrigues ALS, Thacker JS, Gil-Mohapel J (2019) Depression in neurodegenerative diseases: common mechanisms and current treatment options. Neurosci Biobehav Rev 102:56\u201384. https:\/\/doi.org\/10.1016\/j.neubiorev.2019.04.002","journal-title":"Neurosci Biobehav Rev"},{"key":"1499_CR80","doi-asserted-by":"publisher","DOI":"10.3390\/jpm13030385","author":"X Garc\u00eda-Gonz\u00e1lez","year":"2023","unstructured":"Garc\u00eda-Gonz\u00e1lez X, Cubo E, Sim\u00f3n-Vicente L, Mariscal N, Alcaraz R, Aguado L, Rivadeneyra-Posadas J, Sanz-Solas A, Saiz-Rodr\u00edguez M (2023) Pharmacogenetics in the treatment of Huntington\u2019s disease: review and future perspectives. J Pers Med. https:\/\/doi.org\/10.3390\/jpm13030385","journal-title":"J Pers Med"},{"issue":"1","key":"1499_CR81","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/j.1471-4159.1992.tb09283.x","volume":"58","author":"M Garrett","year":"1992","unstructured":"Garrett M, Soares-Da-Silva P (1992) Increased cerebrospinal fluid dopamine and 3, 4-dihydroxyphenylacetic acid levels in Huntington\u2019s disease: evidence for an overactive dopaminergic brain transmission. J Neurochem 58(1):101\u2013106","journal-title":"J Neurochem"},{"issue":"45","key":"1499_CR82","doi-asserted-by":"publisher","first-page":"E3136","DOI":"10.1073\/pnas.1206506109","volume":"109","author":"M Garriga-Canut","year":"2012","unstructured":"Garriga-Canut M, Agust\u00edn-Pav\u00f3n C, Herrmann F, S\u00e1nchez A, Dierssen M, Fillat C, Isalan M (2012) Synthetic zinc finger repressors reduce mutant huntingtin expression in the brain of R6\/2 mice. Proc Natl Acad Sci USA 109(45):E3136\u2013E3145. https:\/\/doi.org\/10.1073\/pnas.1206506109","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"1499_CR83","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12974-024-03038-2","volume":"21","author":"ID Gaudet","year":"2024","unstructured":"Gaudet ID, Xu H, Gordon E, Cannestro GA, Lu ML, Wei J (2024) Elevated SLC7A2 expression is associated with an abnormal neuroinflammatory response and nitrosative stress in Huntington\u2019s disease. J Neuroinflammation 21(1):59. https:\/\/doi.org\/10.1186\/s12974-024-03038-2","journal-title":"J Neuroinflammation"},{"issue":"1","key":"1499_CR84","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.cell.2004.06.018","volume":"118","author":"LR Gauthier","year":"2004","unstructured":"Gauthier LR, Charrin BC, Borrell-Pag\u00e8s M, Dompierre JP, Rangone H, Cordeli\u00e8res FP, De Mey J, MacDonald ME, Lessmann V, Humbert S, Saudou F (2004) Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell 118(1):127\u2013138. https:\/\/doi.org\/10.1016\/j.cell.2004.06.018","journal-title":"Cell"},{"issue":"11","key":"1499_CR85","doi-asserted-by":"publisher","first-page":"2803","DOI":"10.1111\/j.1460-9568.2008.06310.x","volume":"27","author":"JM Gil","year":"2008","unstructured":"Gil JM, Rego AC (2008) Mechanisms of neurodegeneration in Huntington\u2019s disease. Eur J Neurosci 27(11):2803\u20132820. https:\/\/doi.org\/10.1111\/j.1460-9568.2008.06310.x","journal-title":"Eur J Neurosci"},{"issue":"19","key":"1499_CR86","doi-asserted-by":"publisher","first-page":"e2045","DOI":"10.1212\/WNL.0000000000008906","volume":"94","author":"AM Glidden","year":"2020","unstructured":"Glidden AM, Luebbe EA, Elson MJ, Goldenthal SB, Snyder CW, Zizzi CE, Dorsey ER, Heatwole CR (2020) Patient-reported impact of symptoms in Huntington disease: PRISM-HD: PRISM-HD. Neurology 94(19):e2045\u2013e2053. https:\/\/doi.org\/10.1212\/WNL.0000000000008906","journal-title":"Neurology"},{"key":"1499_CR87","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1002\/mds.5557","volume":"17","author":"C Goetz","year":"2002","unstructured":"Goetz C, Koller W, Poewe W, Rascol O, Sampaio C, Brin M, Lees AJ, Lewitt P, Lozano A, Mizuno Y (2002) Amantadine and other antiglutamate agents. Mov Disord 17:S13\u2013S22. https:\/\/doi.org\/10.1002\/mds.5557","journal-title":"Mov Disord"},{"key":"1499_CR88","doi-asserted-by":"publisher","DOI":"10.5334\/tohm.842","author":"M Golsorkhi","year":"2024","unstructured":"Golsorkhi M, Koch J, Pedouim F, Frei K, Bondariyan N, Dashtipour K (2024) Comparative analysis of deutetrabenazine and valbenazine as VMAT2 inhibitors for tardive dyskinesia: a systematic review. Tremor Hyperkinetic Mov. https:\/\/doi.org\/10.5334\/tohm.842","journal-title":"Tremor Hyperkinetic Mov"},{"issue":"6","key":"1499_CR89","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0234394","volume":"15","author":"J Goodliffe","year":"2020","unstructured":"Goodliffe J, Rubakovic A, Chang W, Pathak D, Luebke J (2020) Structural and functional features of medium spiny neurons in the BACHD\u0394N17 mouse model of Huntington\u2019s Disease. PLoS ONE 15(6):e0234394. https:\/\/doi.org\/10.1371\/journal.pone.0234394","journal-title":"PLoS ONE"},{"key":"1499_CR90","doi-asserted-by":"publisher","unstructured":"Gordon M F, Hauser R A, Barkay H, Fernandez HH, Factor SA, Jimenez-Shahed J, Anderson KE (2022) Effects of long-term deutetrabenazine treatment in patients with tardive dyskinesia and underlying psychiatric or mood disorders (P9\u201311.002). https:\/\/doi.org\/10.1212\/WNL.98.18_supplement.1791","DOI":"10.1212\/WNL.98.18_supplement.1791"},{"issue":"1","key":"1499_CR91","doi-asserted-by":"publisher","DOI":"10.1002\/gps.6051","volume":"39","author":"FCE Groenewald","year":"2024","unstructured":"Groenewald FCE, Kok RM (2024) Side effects of clozapine in older adults with treatment-resistant schizophrenia compared to younger adults. Int J Geriatr Psychiatry 39(1):e6051. https:\/\/doi.org\/10.1002\/gps.6051","journal-title":"Int J Geriatr Psychiatry"},{"issue":"11","key":"1499_CR92","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1212\/01.wnl.0000096019.71649.2b","volume":"61","author":"HS Group","year":"2003","unstructured":"Group HS (2003) Dosage effects of riluzole in Huntington\u2019s disease: a multicenter placebo-controlled study. Neurology 61(11):1551\u20131556. https:\/\/doi.org\/10.1212\/01.wnl.0000096019.71649.2b","journal-title":"Neurology"},{"issue":"3","key":"1499_CR93","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1212\/01.wnl.0000198586.85250.13","volume":"66","author":"HS Group","year":"2006","unstructured":"Group HS (2006) Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology 66(3):366\u2013372. https:\/\/doi.org\/10.1212\/01.wnl.0000198586.85250.13","journal-title":"Neurology"},{"key":"1499_CR94","doi-asserted-by":"publisher","first-page":"RRN1259","DOI":"10.1371\/currents.RRN1259","volume":"3","author":"M Groves","year":"2011","unstructured":"Groves M, van Duijn E, Anderson K, Craufurd D, Edmondson MC, Goodman N, van Kammen DP, Goodman L (2011) An international survey-based algorithm for the pharmacologic treatment of irritability in Huntington\u2019s disease. PLoS Curr 3:RRN1259. https:\/\/doi.org\/10.1371\/currents.RRN1259","journal-title":"PLoS Curr"},{"issue":"4","key":"1499_CR95","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.2954","volume":"13","author":"S Gunn","year":"2023","unstructured":"Gunn S, Dale M, Ovaska-Stafford N, Maltby J (2023) Mental health symptoms among those affected by Huntington\u2019s disease: a cross-sectional study. Brain and Behavior 13(4):e2954. https:\/\/doi.org\/10.1002\/brb3.2954","journal-title":"Brain and Behavior"},{"issue":"3","key":"1499_CR96","doi-asserted-by":"publisher","first-page":"36040","DOI":"10.52965\/001c.36040","volume":"10","author":"H Gupta","year":"2022","unstructured":"Gupta H, Perkins W, Stark C, Kikkeri S, Kakazu J, Kaye A, Kaye A (2022) deutetrabenazine for the treatment of chorea associated with Huntington\u2019s disease. Health Psychol Res 10(3):36040. https:\/\/doi.org\/10.52965\/001c.36040","journal-title":"Health Psychol Res"},{"issue":"2","key":"1499_CR97","doi-asserted-by":"publisher","first-page":"170","DOI":"10.4103\/aip.aip_195_22","volume":"7","author":"D Gupta","year":"2023","unstructured":"Gupta D, Bhardwaj A, Ankur A, Ambaliya C (2023) Psychosis and its linear outcomes: Huntington\u2019s disease. Ann Indian Psychiatry 7(2):170\u2013172. https:\/\/doi.org\/10.4103\/aip.aip_195_22","journal-title":"Ann Indian Psychiatry"},{"issue":"19","key":"1499_CR98","doi-asserted-by":"publisher","first-page":"7674","DOI":"10.1523\/jneurosci.18-19-07674.1998","volume":"18","author":"CA Gutekunst","year":"1998","unstructured":"Gutekunst CA, Li SH, Yi H, Ferrante RJ, Li XJ, Hersch SM (1998) The cellular and subcellular localization of huntingtin-associated protein 1 (HAP1): comparison with huntingtin in rat and human. J Neurosci 18(19):7674\u20137686. https:\/\/doi.org\/10.1523\/jneurosci.18-19-07674.1998","journal-title":"J Neurosci"},{"issue":"3","key":"1499_CR99","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1007\/s11033-022-08175-6","volume":"50","author":"JY Han","year":"2023","unstructured":"Han JY, Seo J, Choi Y, Im W, Ban J-J, Sung J-J (2023) CRISPR-Cas9 mediated genome editing of Huntington\u2019s disease neurospheres. Mol Biol Rep 50(3):2127\u20132136. https:\/\/doi.org\/10.1007\/s11033-022-08175-6","journal-title":"Mol Biol Rep"},{"issue":"8","key":"1499_CR100","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S0968-0004(03)00168-3","volume":"28","author":"P Harjes","year":"2003","unstructured":"Harjes P, Wanker EE (2003) The hunt for huntingtin function: interaction partners tell many different stories. Trends Biochem Sci 28(8):425\u2013433. https:\/\/doi.org\/10.1016\/S0968-0004(03)00168-3","journal-title":"Trends Biochem Sci"},{"issue":"6","key":"1499_CR101","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.2174\/1570159X19666211111141246","volume":"20","author":"W Hassan","year":"2022","unstructured":"Hassan W, Noreen H, Rehman S, Kamal MA, da Rocha JBT (2022) Association of oxidative stress with neurological disorders. Curr Neuropharmacol 20(6):1046\u20131072. https:\/\/doi.org\/10.2174\/1570159X19666211111141246","journal-title":"Curr Neuropharmacol"},{"issue":"1","key":"1499_CR102","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/nrd2784","volume":"8","author":"MR Hayden","year":"2009","unstructured":"Hayden MR, Leavitt BR, Yasothan U, Kirkpatrick P (2009) Tetrabenazine. Nat Rev Drug Discov 8(1):17\u201318. https:\/\/doi.org\/10.1038\/nrd2784","journal-title":"Nat Rev Drug Discov"},{"key":"1499_CR103","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1007\/978-3-031-15080-7_226","volume-title":"Handbook of neurotoxicity","author":"A Heinz","year":"2023","unstructured":"Heinz A, Nabariya DK, Krau\u00df S (2023) Huntington\u2019s disease and neurodegeneration. Handbook of neurotoxicity. Springer, Cham, pp 1765\u20131787. https:\/\/doi.org\/10.1007\/978-3-031-15080-7_226"},{"issue":"10","key":"1499_CR104","doi-asserted-by":"publisher","first-page":"3200","DOI":"10.1523\/JNEUROSCI.5599-08.2009","volume":"29","author":"MY Heng","year":"2009","unstructured":"Heng MY, Detloff PJ, Wang PL, Tsien JZ, Albin RL (2009) In vivo evidence for NMDA receptor-mediated excitotoxicity in a murine genetic model of Huntington disease. J Neurosci 29(10):3200\u20133205. https:\/\/doi.org\/10.1523\/JNEUROSCI.5599-08.2009","journal-title":"J Neurosci"},{"issue":"17","key":"1499_CR105","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1007\/s40265-017-0831-0","volume":"77","author":"Y-A Heo","year":"2017","unstructured":"Heo Y-A, Scott LJ (2017) Deutetrabenazine: a review in chorea associated with Huntington\u2019s disease. Drugs 77(17):1857\u20131864. https:\/\/doi.org\/10.1007\/s40265-017-0831-0","journal-title":"Drugs"},{"issue":"1","key":"1499_CR106","doi-asserted-by":"publisher","first-page":"99","DOI":"10.3233\/JHD-190381","volume":"9","author":"DC Hergert","year":"2020","unstructured":"Hergert DC, Sanchez-Ramos J, Cimino CR (2020) Awareness of chorea in Huntington\u2019s disease. J Huntington\u2019s Dis 9(1):99\u2013103. https:\/\/doi.org\/10.3233\/JHD-190381","journal-title":"J Huntington\u2019s Dis"},{"key":"1499_CR107","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.88.16_supplement.p2.006","author":"S Hersch","year":"2017","unstructured":"Hersch S, Claassen D, Edmondson M, Wild E, Guerciolini R, Panzara M (2017) Multicenter, randomized, double-blind, placebo-controlled phase 1b\/2a studies of WVE-120101 and WVE-120102 in patients with Huntington\u2019s disease (P2. 006). AAN Enterp. https:\/\/doi.org\/10.1212\/wnl.88.16_supplement.p2.006","journal-title":"AAN Enterp"},{"issue":"8","key":"1499_CR108","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1002\/j.1460-2075.1990.tb07423.x","volume":"9","author":"M Hofer","year":"1990","unstructured":"Hofer M, Pagliusi SR, Hohn A, Leibrock J, Barde YA (1990) Regional distribution of brain-derived neurotrophic factor mRNA in the adult mouse brain. EMBO J 9(8):2459\u20132464. https:\/\/doi.org\/10.1002\/j.1460-2075.1990.tb07423.x","journal-title":"EMBO J"},{"issue":"4","key":"1499_CR109","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/s0300-9084(02)01398-6","volume":"84","author":"G Hoffner","year":"2002","unstructured":"Hoffner G, Djian P (2002) Protein aggregation in Huntington\u2019s disease. Biochimie 84(4):273\u2013278. https:\/\/doi.org\/10.1016\/s0300-9084(02)01398-6","journal-title":"Biochimie"},{"issue":"1","key":"1499_CR110","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3233\/JHD-200427","volume":"10","author":"EP Hong","year":"2021","unstructured":"Hong EP, MacDonald ME, Wheeler VC, Jones L, Holmans P, Orth M, Monckton DG, Long JD, Kwak S, Gusella JF, Lee J-M (2021) Huntington\u2019s disease pathogenesis: two sequential components. J Huntington\u2019s Dis 10(1):35\u201351. https:\/\/doi.org\/10.3233\/JHD-200427","journal-title":"J Huntington\u2019s Dis"},{"issue":"1","key":"1499_CR111","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s10020-024-00801-2","volume":"30","author":"F Hoschek","year":"2024","unstructured":"Hoschek F, Natan J, Wagner M, Sathasivam K, Abdelmoez A, von Einem B, Bates GP, Landwehrmeyer GB, Neueder A (2024) Huntingtin HTT1a is generated in a CAG repeat-length-dependent manner in human tissues. Mol Med 30(1):36. https:\/\/doi.org\/10.1186\/s10020-024-00801-2","journal-title":"Mol Med"},{"issue":"4","key":"1499_CR112","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1080\/13803390600718958","volume":"29","author":"KF Hoth","year":"2007","unstructured":"Hoth KF, Paulsen JS, Moser DJ, Tranel D, Clark LA, Bechara A (2007) Patients with Huntington\u2019s disease have impaired awareness of cognitive, emotional, and functional abilities. J Clin Exp Neuropsychol 29(4):365\u2013376. https:\/\/doi.org\/10.1080\/13803390600718958","journal-title":"J Clin Exp Neuropsychol"},{"issue":"9","key":"1499_CR113","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1038\/nbt.2647","volume":"31","author":"PD Hsu","year":"2013","unstructured":"Hsu PD, Scott DA, Weinstein JA, Ran FA, Konermann S, Agarwala V, Li Y, Fine EJ, Wu X, Shalem O, Cradick TJ, Marraffini LA, Bao G, Zhang F (2013) DNA targeting specificity of RNA-guided Cas9 nucleases. Nat Biotechnol 31(9):827\u2013832. https:\/\/doi.org\/10.1038\/nbt.2647","journal-title":"Nat Biotechnol"},{"issue":"10","key":"1499_CR114","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1002\/mds.25362","volume":"28","author":"H Investigators","year":"2013","unstructured":"Investigators H (2013) A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington\u2019s disease. Mov Disord 28(10):1407\u20131415. https:\/\/doi.org\/10.1002\/mds.25362","journal-title":"Mov Disord"},{"issue":"1","key":"1499_CR115","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1023\/a:1023228626309","volume":"15","author":"MM Iqbal","year":"2003","unstructured":"Iqbal MM, Rahman A, Husain Z, Mahmud SZ, Ryan WG, Feldman JM (2003) Clozapine: a clinical review of adverse effects and management. Ann Clin Psychiatry 15(1):33\u201348. https:\/\/doi.org\/10.1023\/a:1023228626309","journal-title":"Ann Clin Psychiatry"},{"key":"1499_CR116","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2023.148081","volume":"897","author":"S Jana","year":"2024","unstructured":"Jana S, Giri B, Das S, Manna A, Mandal SC, Ranjan JN (2024) Azadiradione up-regulates the expression of parvalbumin and BDNF via Ube3a. Gene 897:148081. https:\/\/doi.org\/10.1016\/j.gene.2023.148081","journal-title":"Gene"},{"issue":"10","key":"1499_CR117","doi-asserted-by":"publisher","first-page":"5112","DOI":"10.1007\/s12035-021-02451-5","volume":"58","author":"L Jing","year":"2021","unstructured":"Jing L, Cheng S, Pan Y, Liu Q, Yang W, Li S, Li X-J (2021) Accumulation of endogenous mutant huntingtin in astrocytes exacerbates neuropathology of Huntington disease in mice. Mol Neurobiol 58(10):5112\u20135126. https:\/\/doi.org\/10.1007\/s12035-021-02451-5","journal-title":"Mol Neurobiol"},{"key":"1499_CR118","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13073-017-0450-0","volume":"9","author":"JC Kaczmarek","year":"2017","unstructured":"Kaczmarek JC, Kowalski PS, Anderson DG (2017) Advances in the delivery of RNA therapeutics: from concept to clinical reality. Genome Med 9:1\u201316. https:\/\/doi.org\/10.1186\/s13073-017-0450-0","journal-title":"Genome Med"},{"issue":"3","key":"1499_CR119","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1159\/000449184","volume":"23","author":"N Kaur","year":"2016","unstructured":"Kaur N, Kumar P, Jamwal S, Deshmukh R, Gauttam V (2016) Tetrabenazine: spotlight on drug review. Ann Neurosci 23(3):176\u2013185. https:\/\/doi.org\/10.1159\/000449184","journal-title":"Ann Neurosci"},{"issue":"R1","key":"1499_CR120","doi-asserted-by":"publisher","first-page":"R53","DOI":"10.1093\/hmg\/ddv442","volume":"25","author":"MS Keiser","year":"2016","unstructured":"Keiser MS, Kordasiewicz HB, McBride JL (2016) Gene suppression strategies for dominantly inherited neurodegenerative diseases: lessons from Huntington\u2019s disease and spinocerebellar ataxia. Hum Mol Genet 25(R1):R53-64. https:\/\/doi.org\/10.1093\/hmg\/ddv442","journal-title":"Hum Mol Genet"},{"issue":"22","key":"1499_CR121","doi-asserted-by":"publisher","first-page":"12784","DOI":"10.1073\/pnas.221451398","volume":"98","author":"YJ Kim","year":"2001","unstructured":"Kim YJ, Yi Y, Sapp E, Wang Y, Cuiffo B, Kegel KB, Qin ZH, Aronin N, DiFiglia M (2001) Caspase 3-cleaved N-terminal fragments of wild-type and mutant huntingtin are present in normal and Huntington\u2019s disease brains, associate with membranes, and undergo calpain-dependent proteolysis. Proc Natl Acad Sci USA 98(22):12784\u201312789. https:\/\/doi.org\/10.1073\/pnas.221451398","journal-title":"Proc Natl Acad Sci USA"},{"issue":"20","key":"1499_CR122","doi-asserted-by":"publisher","first-page":"3919","DOI":"10.1093\/hmg\/ddq306","volume":"19","author":"J Kim","year":"2010","unstructured":"Kim J, Moody JP, Edgerly CK, Bordiuk OL, Cormier K, Smith K, Beal MF, Ferrante RJ (2010) Mitochondrial loss, dysfunction and altered dynamics in Huntington\u2019s disease. Hum Mol Genet 19(20):3919\u20133935. https:\/\/doi.org\/10.1093\/hmg\/ddq306","journal-title":"Hum Mol Genet"},{"issue":"16","key":"1499_CR123","doi-asserted-by":"publisher","first-page":"8363","DOI":"10.3390\/ijms22168363","volume":"22","author":"A Kim","year":"2021","unstructured":"Kim A, Lalonde K, Truesdell A, Gomes Welter P, Brocardo PS, Rosenstock TR, Gil-Mohapel J (2021) New avenues for the treatment of Huntington\u2019s disease. Int J Mol Sci 22(16):8363. https:\/\/doi.org\/10.3390\/ijms22168363","journal-title":"Int J Mol Sci"},{"issue":"3","key":"1499_CR124","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1002\/ana.410220318","volume":"22","author":"SJ Kish","year":"1987","unstructured":"Kish SJ, Shannak K, Hornykiewicz O (1987) Elevated serotonin and reduced dopamine in subregionally divided Huntington\u2019s disease striatum. Ann Neurol 22(3):386\u2013389. https:\/\/doi.org\/10.1002\/ana.410220318","journal-title":"Ann Neurol"},{"issue":"12","key":"1499_CR125","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1002\/jnr.24495","volume":"97","author":"ET Koch","year":"2019","unstructured":"Koch ET, Raymond LA (2019) Dysfunctional striatal dopamine signaling in Huntington\u2019s disease. J Neurosci Res 97(12):1636\u20131654. https:\/\/doi.org\/10.1002\/jnr.24495","journal-title":"J Neurosci Res"},{"issue":"4","key":"1499_CR126","doi-asserted-by":"publisher","first-page":"754","DOI":"10.3390\/ijms18040754","volume":"18","author":"N Kolli","year":"2017","unstructured":"Kolli N, Lu M, Maiti P, Rossignol J, Dunbar GL (2017) CRISPR-Cas9 mediated gene-silencing of the mutant huntingtin gene in an in vitro model of Huntington\u2019s disease. Int J Mol Sci 18(4):754. https:\/\/doi.org\/10.3390\/ijms18040754","journal-title":"Int J Mol Sci"},{"key":"1499_CR127","doi-asserted-by":"publisher","first-page":"CD006626","DOI":"10.1002\/14651858.CD006626.pub2","volume":"1","author":"K Komossa","year":"2011","unstructured":"Komossa K, Rummel-Kluge C, Schwarz S, Schmid F, Hunger H, Kissling W, Leucht S (2011) Risperidone versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 1:CD006626. https:\/\/doi.org\/10.1002\/14651858.CD006626.pub2","journal-title":"Cochrane Database Syst Rev"},{"issue":"1\u20132","key":"1499_CR128","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s10863-012-9479-3","volume":"45","author":"J Krzyszto\u0144-Russjan","year":"2013","unstructured":"Krzyszto\u0144-Russjan J, Zielonka D, Jackiewicz J, Ku\u015bmirek S, Bubko I, Klimberg A, Marcinkowski JT, Anuszewska EL (2013) A study of molecular changes relating to energy metabolism and cellular stress in people with Huntington\u2019s disease: looking for biomarkers. J Bioenerg Biomembr 45(1\u20132):71\u201385. https:\/\/doi.org\/10.1007\/s10863-012-9479-3","journal-title":"J Bioenerg Biomembr"},{"issue":"3","key":"1499_CR129","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3233\/jhd-160205","volume":"5","author":"A Kumar","year":"2016","unstructured":"Kumar A, Ratan RR (2016) Oxidative stress and Huntington\u2019s disease: the good, the bad, and the ugly. J Huntington\u2019s Dis 5(3):217\u2013237. https:\/\/doi.org\/10.3233\/jhd-160205","journal-title":"J Huntington\u2019s Dis"},{"issue":"7S_Part_12","key":"1499_CR130","doi-asserted-by":"publisher","first-page":"P637","DOI":"10.1016\/j.jalz.2017.06.730","volume":"13","author":"P Kumar Jr","year":"2017","unstructured":"Kumar P Jr (2017) [P2\u2013081]: Possible involvement of calcium channels in neuroprotective mechanism of fenofibrate against 3-nitropropionic acid-induced Huntington\u2019s disease in rats. Alzheimer\u2019s Dementia 13(7S_Part_12):P637\u2013P637. https:\/\/doi.org\/10.1016\/j.jalz.2017.06.730","journal-title":"Alzheimer\u2019s Dementia"},{"issue":"1","key":"1499_CR131","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3390\/brainsci10010043","volume":"10","author":"A Kumar","year":"2020","unstructured":"Kumar A, Kumar V, Singh K, Kumar S, Kim Y-S, Lee Y-M, Kim J-J (2020) Therapeutic advances for Huntington\u2019s disease. Brain Sci 10(1):43. https:\/\/doi.org\/10.3390\/brainsci10010043","journal-title":"Brain Sci"},{"issue":"93","key":"1499_CR132","doi-asserted-by":"publisher","first-page":"A96","DOI":"10.1136\/jnnp-2022-ehdn.258","volume":"2022","author":"R Kumar","year":"2022","unstructured":"Kumar R, Claassen DO, Mongan A, Hoehn B, Lin P, Cahir-Mcfarland E, Taylor L, Chandra P, Yednock T, Kroon H-A (2022) J08 A phase 2 open label study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous ANX005 in patients with, or at risk of, manifest Huntington\u2019s disease (HD). J Neurol Neurosurg Psychiatry 2022(93):A96\u2013A97. https:\/\/doi.org\/10.1136\/jnnp-2022-ehdn.258","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1499_CR133","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.bbrc.2023.02.075","volume":"655","author":"D Kumar","year":"2023","unstructured":"Kumar D, Hasan GM, Islam A, Hassan MI (2023a) Therapeutic targeting of Huntington\u2019s disease: molecular and clinical approaches. Biochem Biophys Res Commun 655:18\u201324. https:\/\/doi.org\/10.1016\/j.bbrc.2023.02.075","journal-title":"Biochem Biophys Res Commun"},{"issue":"17_supplement_2","key":"1499_CR134","doi-asserted-by":"publisher","first-page":"3366","DOI":"10.1212\/WNL.0000000000203217","volume":"100","author":"R Kumar","year":"2023","unstructured":"Kumar R, Claassen D, Mongan A, Hoehn B, Lin P, Cahir-Mcfarland E, Guo C, Volman V, Taylor L, Chandra P, Yednock T, Kroon H-A (2023b) A phase 2 open-label study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous ANX005 in patients with, or at risk of, manifest Huntington\u2019s disease (HD) (S32.009). Neurology 100(17_supplement_2):3366. https:\/\/doi.org\/10.1212\/WNL.0000000000203217","journal-title":"Neurology"},{"issue":"4","key":"1499_CR135","doi-asserted-by":"publisher","first-page":"e367","DOI":"10.1212\/nxi.0000000000000367","volume":"4","author":"C LaGanke","year":"2017","unstructured":"LaGanke C, Samkoff L, Edwards K, Jung Henson L, Repovic P, Lynch S, Stone L, Mattson D, Galluzzi A, Fisher TL, Reilly C, Winter LA, Leonard JE, Zauderer M (2017) Safety\/tolerability of the anti-semaphorin 4D antibody VX15\/2503 in a randomized phase 1 trial. Neurol Neuroimmunol Neuroinflamm 4(4):e367. https:\/\/doi.org\/10.1212\/nxi.0000000000000367","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"7","key":"1499_CR136","doi-asserted-by":"publisher","first-page":"5297","DOI":"10.1523\/jneurosci.15-07-05297.1995","volume":"15","author":"GB Landwehrmeyer","year":"1995","unstructured":"Landwehrmeyer GB, Standaert DG, Testa CM, Penney JB Jr, Young AB (1995) NMDA receptor subunit mRNA expression by projection neurons and interneurons in rat striatum. J Neurosci 15(7):5297\u20135307. https:\/\/doi.org\/10.1523\/jneurosci.15-07-05297.1995","journal-title":"J Neurosci"},{"issue":"3","key":"1499_CR137","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1002\/ana.21181","volume":"62","author":"GB Landwehrmeyer","year":"2007","unstructured":"Landwehrmeyer GB, Dubois B, de Y\u00e9benes JG, Kremer B, Gaus W, Kraus PH, Przuntek H, Dib M, Doble A, Fischer W, Ludolph AC, European Huntington\u2019s Disease Initiative Study Group (2007) Riluzole in Huntington\u2019s disease: a 3-year, randomized controlled study. Ann Neurol 62(3):262\u2013272. https:\/\/doi.org\/10.1002\/ana.21181","journal-title":"Ann Neurol"},{"issue":"3","key":"1499_CR138","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.tig.2004.01.008","volume":"20","author":"S-H Li","year":"2004","unstructured":"Li S-H, Li X-J (2004) Huntingtin-protein interactions and the pathogenesis of Huntington\u2019s disease. Trends in Genetics: TIG 20(3):146\u2013154. https:\/\/doi.org\/10.1016\/j.tig.2004.01.008","journal-title":"Trends in Genetics: TIG"},{"issue":"6","key":"1499_CR139","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.cmet.2005.05.004","volume":"1","author":"J Lin","year":"2005","unstructured":"Lin J, Handschin C, Spiegelman BM (2005) Metabolic control through the PGC-1 family of transcription coactivators. Cell Metab 1(6):361\u2013370. https:\/\/doi.org\/10.1016\/j.cmet.2005.05.004","journal-title":"Cell Metab"},{"issue":"2","key":"1499_CR140","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/s1097-2765(02)00602-0","volume":"10","author":"A Lunkes","year":"2002","unstructured":"Lunkes A, Lindenberg KS, Ben-Ha\u00efem L, Weber C, Devys D, Landwehrmeyer GB, Mandel J-L, Trottier Y (2002) Proteases acting on mutant huntingtin generate cleaved products that differentially build up cytoplasmic and nuclear inclusions. Mol Cell 10(2):259\u2013269. https:\/\/doi.org\/10.1016\/s1097-2765(02)00602-0","journal-title":"Mol Cell"},{"issue":"3","key":"1499_CR141","doi-asserted-by":"publisher","first-page":"314","DOI":"10.2174\/1567202620666230721122957","volume":"20","author":"K Maiese","year":"2023","unstructured":"Maiese K (2023) The metabolic basis for nervous system dysfunction in Alzheimer\u2019s disease, Parkinson\u2019s Disease, and Huntington\u2019s disease. Curr Neurovasc Res 20(3):314\u2013333. https:\/\/doi.org\/10.2174\/1567202620666230721122957","journal-title":"Curr Neurovasc Res"},{"key":"1499_CR142","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.semcdb.2015.03.005","volume":"40","author":"M Martinez-Vicente","year":"2015","unstructured":"Martinez-Vicente M (2015) Autophagy in neurodegenerative diseases: from pathogenic dysfunction to therapeutic modulation. Semin Cell Dev Biol 40:115\u2013126. https:\/\/doi.org\/10.1016\/j.semcdb.2015.03.005","journal-title":"Semin Cell Dev Biol"},{"issue":"5","key":"1499_CR143","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/nn.2528","volume":"13","author":"M Martinez-Vicente","year":"2010","unstructured":"Martinez-Vicente M, Talloczy Z, Wong E, Tang G, Koga H, Kaushik S, de Vries R, Arias E, Harris S, Sulzer D, Cuervo AM (2010) Cargo recognition failure is responsible for inefficient autophagy in Huntington\u2019s disease. Nat Neurosci 13(5):567\u2013576. https:\/\/doi.org\/10.1038\/nn.2528","journal-title":"Nat Neurosci"},{"issue":"6","key":"1499_CR144","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.3390\/ijms21062146","volume":"21","author":"F Marxreiter","year":"2020","unstructured":"Marxreiter F, Stemick J, Kohl Z (2020) Huntingtin lowering strategies. Int J Mol Sci 21(6):2146. https:\/\/doi.org\/10.3390\/ijms21062146","journal-title":"Int J Mol Sci"},{"key":"1499_CR145","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinme.2024.100200","volume":"6","author":"TH Massey","year":"2024","unstructured":"Massey TH, McLauchlan DJ (2024) Huntington\u2019s disease: a clinical primer for acute and general physicians. Clin Med (lond) 6:100200. https:\/\/doi.org\/10.1016\/j.clinme.2024.100200","journal-title":"Clin Med (lond)"},{"issue":"4","key":"1499_CR146","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1002\/jcb.24432","volume":"114","author":"C Maucksch","year":"2013","unstructured":"Maucksch C, Vazey EM, Gordon RJ, Connor B (2013) Stem cell-based therapy for Huntington\u2019s disease. J Cell Biochem 114(4):754\u2013763. https:\/\/doi.org\/10.1002\/jcb.24432","journal-title":"J Cell Biochem"},{"key":"1499_CR147","first-page":"1163","volume":"13","author":"MC Mauri","year":"2014","unstructured":"Mauri MC, Paletta S, Maffini M, Colasanti A, Dragogna F, Di Pace C, Altamura AC (2014) Clinical pharmacology of atypical antipsychotics: an update. EXCLI J 13:1163\u20131191","journal-title":"EXCLI J"},{"issue":"8","key":"1499_CR148","doi-asserted-by":"publisher","first-page":"3558","DOI":"10.1172\/JCI99081","volume":"128","author":"A McCampbell","year":"2018","unstructured":"McCampbell A, Cole T, Wegener AJ, Tomassy GS, Setnicka A, Farley BJ, Schoch KM, Hoye ML, Shabsovich M, Sun L, Luo Y, Zhang M, Comfort N, Wang B, Amacker J, Thankamony S, Salzman DW, Cudkowicz M, Graham DL, Miller TM (2018) Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models. J Clin Investig 128(8):3558\u20133567. https:\/\/doi.org\/10.1172\/JCI99081","journal-title":"J Clin Investig"},{"issue":"23","key":"1499_CR149","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1056\/NEJMc2300400","volume":"389","author":"P McColgan","year":"2023","unstructured":"McColgan P, Thobhani A, Boak L, Schobel SA, Nicotra A, Palermo G, Trundell D, Zhou J, Schlegel V, Sanwald Ducray P, Hawellek DJ, Dorn J, Simillion C, Lindemann M, Wheelock V, Durr A, Anderson KE, Long JD, Wild EJ, GENERATION HD1 Investigators (2023) Tominersen in adults with manifest Huntington\u2019s disease. New England J Med 389(23):2203\u20132205. https:\/\/doi.org\/10.1056\/NEJMc2300400","journal-title":"New England J Med"},{"key":"1499_CR150","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.14029","author":"R Mehanna","year":"2024","unstructured":"Mehanna R, Jankovic J (2024) Systemic symptoms in huntington\u2019s disease: a comprehensive review. Mov Disord Clin Pract. https:\/\/doi.org\/10.1002\/mdc3.14029","journal-title":"Mov Disord Clin Pract"},{"issue":"2","key":"1499_CR151","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s11910-017-0711-8","volume":"17","author":"TA Mestre","year":"2017","unstructured":"Mestre TA, Sampaio C (2017) Huntington disease: linking pathogenesis to the development of experimental therapeutics. Curr Neurol Neurosci Rep 17(2):18. https:\/\/doi.org\/10.1007\/s11910-017-0711-8","journal-title":"Curr Neurol Neurosci Rep"},{"key":"1499_CR152","doi-asserted-by":"publisher","first-page":"CD006456","DOI":"10.1002\/14651858.CD006456.pub2","volume":"3","author":"T Mestre","year":"2009","unstructured":"Mestre T, Ferreira J, Coelho MM, Rosa M, Sampaio C (2009) Therapeutic interventions for symptomatic treatment in Huntington\u2019s disease. Cochrane Database Syst Revi 3:CD006456. https:\/\/doi.org\/10.1002\/14651858.CD006456.pub2","journal-title":"Cochrane Database Syst Revi"},{"issue":"5","key":"1499_CR153","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1212\/wnl.59.5.694","volume":"59","author":"LV Metman","year":"2002","unstructured":"Metman LV, Morris M, Farmer C, Gillespie M, Mosby K, Wuu J, Chase T (2002) Huntington\u2019s disease: a randomized, controlled trial using the NMDA-antagonist amantadine. Neurology 59(5):694\u2013699. https:\/\/doi.org\/10.1212\/wnl.59.5.694","journal-title":"Neurology"},{"key":"1499_CR154","doi-asserted-by":"publisher","first-page":"CD001447","DOI":"10.1002\/14651858.CD001447.pub3","volume":"3","author":"RG Miller","year":"2012","unstructured":"Miller RG, Mitchell JD, Moore DH (2012) Riluzole for amyotrophic lateral sclerosis (ALS)\/motor neuron disease (MND). Cochrane Database of Syst Rev 3:CD001447. https:\/\/doi.org\/10.1002\/14651858.CD001447.pub3","journal-title":"Cochrane Database of Syst Rev"},{"key":"1499_CR155","unstructured":"Mintz M (2023)\u00a0Huntington\u2019s disease: a systematic review and overview of treatments."},{"issue":"4","key":"1499_CR156","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1007\/s11064-008-9843-1","volume":"34","author":"I Miyazaki","year":"2009","unstructured":"Miyazaki I, Asanuma M (2009) Approaches to prevent dopamine quinone-induced neurotoxicity. Neurochem Res 34(4):698\u2013706. https:\/\/doi.org\/10.1007\/s11064-008-9843-1","journal-title":"Neurochem Res"},{"issue":"1","key":"1499_CR157","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ymthe.2016.11.010","volume":"25","author":"AM Monteys","year":"2017","unstructured":"Monteys AM, Ebanks SA, Keiser MS, Davidson BL (2017) CRISPR\/Cas9 editing of the mutant huntingtin allele in vitro and in vivo. Mol Ther 25(1):12\u201323. https:\/\/doi.org\/10.1016\/j.ymthe.2016.11.010","journal-title":"Mol Ther"},{"issue":"10","key":"1499_CR158","doi-asserted-by":"publisher","first-page":"4990","DOI":"10.5958\/0974-360X.2020.00874.4","volume":"13","author":"BB Moon","year":"2020","unstructured":"Moon BB, Dahikar GD, Ganjiwale RO (2020) A Review on Huntington\u2019s disease. Res J Pharm Technol 13(10):4990\u20134995. https:\/\/doi.org\/10.5958\/0974-360X.2020.00874.4","journal-title":"Res J Pharm Technol"},{"key":"1499_CR300","doi-asserted-by":"publisher","unstructured":"Morales E, Herrera C, Monta\u00f1o L, Meza M, Del Villar N, Mendoza X, Rodr\u00edguez A (2022) Current knowledge and future directions in Huntington\u2019s disease. Arch Neurocien 27(4):31\u201343. https:\/\/doi.org\/10.31157\/an.v1iinpress.346","DOI":"10.31157\/an.v1iinpress.346"},{"issue":"1","key":"1499_CR159","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s12035-014-8735-4","volume":"51","author":"L Naia","year":"2015","unstructured":"Naia L, Ferreira IL, Cunha-Oliveira T, Duarte AI, Ribeiro M, Rosenstock TR, La\u00e7o MN, Ribeiro MJ, Oliveira CR, Saudou F, Humbert S, Rego AC (2015) Activation of IGF-1 and insulin signaling pathways ameliorate mitochondrial function and energy metabolism in Huntington\u2019s disease human lymphoblasts. Mol Neurobiol 51(1):331\u2013348. https:\/\/doi.org\/10.1007\/s12035-014-8735-4","journal-title":"Mol Neurobiol"},{"key":"1499_CR160","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.npep.2016.01.009","volume":"58","author":"L Naia","year":"2016","unstructured":"Naia L, Ribeiro M, Rodrigues J, Duarte AI, Lopes C, Rosenstock TR, Hayden MR, Rego AC (2016) Insulin and IGF-1 regularize energy metabolites in neural cells expressing full-length mutant huntingtin. Neuropeptides 58:73\u201381. https:\/\/doi.org\/10.1016\/j.npep.2016.01.009","journal-title":"Neuropeptides"},{"issue":"3","key":"1499_CR161","doi-asserted-by":"publisher","first-page":"19","DOI":"10.32607\/20758251-2014-6-3-19-40","volume":"6","author":"AA Nemudryi","year":"2014","unstructured":"Nemudryi AA, Valetdinova KR, Medvedev SP, Zakian SM (2014) TALEN and CRISPR\/Cas genome editing systems: Tools of discovery. Acta Nat 6(3):19\u201340. https:\/\/doi.org\/10.32607\/20758251-2014-6-3-19-40","journal-title":"Acta Nat"},{"key":"1499_CR162","doi-asserted-by":"publisher","DOI":"10.17179\/excli2023-6155","author":"JN Nojadeh","year":"2023","unstructured":"Nojadeh JN, Eryilmaz N, Erg\u00fcder B\u0130 (2023) CRISPR\/Cas9 genome editing for neurodegenerative diseases. EXCLI J. https:\/\/doi.org\/10.17179\/excli2023-6155","journal-title":"EXCLI J"},{"issue":"7","key":"1499_CR163","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1001\/archneur.60.7.996","volume":"60","author":"P O\u2019Suilleabhain","year":"2003","unstructured":"O\u2019Suilleabhain P, Dewey RB Jr (2003) A randomized trial of amantadine in Huntington disease. Arch Neurol 60(7):996\u2013998. https:\/\/doi.org\/10.1001\/archneur.60.7.996","journal-title":"Arch Neurol"},{"issue":"11","key":"1499_CR164","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1038\/s41593-022-01185-4","volume":"25","author":"YM Oh","year":"2022","unstructured":"Oh YM, Lee SW, Kim WK, Chen S, Church VA, Cates K, Yoo AS (2022) Age-related Huntington\u2019s disease progression modeled in directly reprogrammed patient-derived striatal neurons highlights impaired autophagy. Nat Neurosci 25(11):1420\u20131433. https:\/\/doi.org\/10.1038\/s41593-022-01185-4","journal-title":"Nat Neurosci"},{"issue":"3","key":"1499_CR165","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.4049\/jimmunol.0903302","volume":"184","author":"T Okuno","year":"2010","unstructured":"Okuno T, Nakatsuji Y, Moriya M, Takamatsu H, Nojima S, Takegahara N, Toyofuku T, Nakagawa Y, Kang S, Friedel RH, Sakoda S, Kikutani H, Kumanogoh A (2010) Roles of Sema4D-plexin-B1 interactions in the central nervous system for pathogenesis of experimental autoimmune encephalomyelitis. J Immunol 184(3):1499\u20131506. https:\/\/doi.org\/10.4049\/jimmunol.0903302","journal-title":"J Immunol"},{"issue":"1","key":"1499_CR166","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3233\/JHD-180335","volume":"8","author":"M Oosterloo","year":"2019","unstructured":"Oosterloo M, Craufurd D, Nijsten H, van Duijn E (2019) Obsessive-compulsive and perseverative behaviors in Huntington\u2019s disease. J Huntington\u2019s Dis 8(1):1\u20137. https:\/\/doi.org\/10.3233\/JHD-180335","journal-title":"J Huntington\u2019s Dis"},{"key":"1499_CR167","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1371\/currents.RRN1184","volume":"2","author":"M Orth","year":"2010","unstructured":"Orth M, Handley OJ, Schwenke C, Dunnett SB, Craufurd D, Ho AK, Wild E, Tabrizi SJ, Landwehrmeyer GB, Investigators of the European Huntington\u2019s Disease Network (2010) Observing Huntington\u2019s disease: The European Huntington\u2019s disease network\u2019s REGISTRY. PLoS Curr 2:1184. https:\/\/doi.org\/10.1371\/currents.RRN1184","journal-title":"PLoS Curr"},{"issue":"2","key":"1499_CR168","doi-asserted-by":"publisher","first-page":"149","DOI":"10.3233\/JHD-230567","volume":"12","author":"NE Owen","year":"2023","unstructured":"Owen NE, Barker RA, Voysey ZJ (2023) Sleep dysfunction in Huntington\u2019s disease: impacts of current medications and prospects for treatment. J Huntington\u2019s Dis 12(2):149\u2013161. https:\/\/doi.org\/10.3233\/JHD-230567","journal-title":"J Huntington\u2019s Dis"},{"issue":"1","key":"1499_CR169","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3892\/br.2022.1587","volume":"18","author":"AM Palaiogeorgou","year":"2023","unstructured":"Palaiogeorgou AM, Papakonstantinou E, Golfinopoulou R, Sigala M, Mitsis T, Papageorgiou L, Diakou I, Pierouli K, Dragoumani K, Spandidos DA, Bacopoulou F, Chrousos GP, Eliopoulos E, Vlachakis D (2023) Recent approaches on Huntington\u2019s disease (Review). Biomed Rep 18(1):5. https:\/\/doi.org\/10.3892\/br.2022.1587","journal-title":"Biomed Rep"},{"issue":"6","key":"1499_CR170","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1034\/j.1600-0404.2002.01197.x","volume":"105","author":"D Paleacu","year":"2002","unstructured":"Paleacu D, Anca M, Giladi N (2002) Olanzapine in Huntington\u2019s disease: olanzapine in Huntington\u2019s disease. Acta Neurol Scand 105(6):441\u2013444. https:\/\/doi.org\/10.1034\/j.1600-0404.2002.01197.x","journal-title":"Acta Neurol Scand"},{"key":"1499_CR171","doi-asserted-by":"publisher","first-page":"258","DOI":"10.3389\/fnmol.2019.00258","volume":"12","author":"TH Palpagama","year":"2019","unstructured":"Palpagama TH, Waldvogel HJ, Faull RLM, Kwakowsky A (2019) The role of microglia and astrocytes in Huntington\u2019s disease. Front Mol Neurosci 12:258. https:\/\/doi.org\/10.3389\/fnmol.2019.00258","journal-title":"Front Mol Neurosci"},{"issue":"3","key":"1499_CR172","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s11910-021-01093-3","volume":"21","author":"L Pan","year":"2021","unstructured":"Pan L, Feigin A (2021) Huntington\u2019s disease: new frontiers in therapeutics. Curr Neurol Neurosci Rep 21(3):10. https:\/\/doi.org\/10.1007\/s11910-021-01093-3","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"8","key":"1499_CR173","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/nn884","volume":"5","author":"AV Panov","year":"2002","unstructured":"Panov AV, Gutekunst C-A, Leavitt BR, Hayden MR, Burke JR, Strittmatter WJ, Greenamyre JT (2002) Early mitochondrial calcium defects in Huntington\u2019s disease are a direct effect of polyglutamines. Nat Neurosci 5(8):731\u2013736. https:\/\/doi.org\/10.1038\/nn884","journal-title":"Nat Neurosci"},{"key":"1499_CR174","doi-asserted-by":"publisher","DOI":"10.1016\/j.mito.2020.08.003","author":"P Pantiya","year":"2020","unstructured":"Pantiya P, Thonusin C, Chattipakorn N, Chattipakorn SC (2020) Mitochondrial abnormalities in neurodegenerative models and possible interventions: focus on Alzheimer\u2019s disease, Parkinson\u2019s disease. Huntington\u2019s Dis Mitochondrion. https:\/\/doi.org\/10.1016\/j.mito.2020.08.003","journal-title":"Huntington\u2019s Dis Mitochondrion"},{"key":"1499_CR175","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/978-3-031-32815-2_17","volume-title":"Biomarkers for Huntington\u2019s disease: improving clinical outcomes","author":"GM Parkin","year":"2023","unstructured":"Parkin GM, Corey-Bloom J (2023) Considerations and advances in Huntington\u2019s disease clinical trial design. Biomarkers for Huntington\u2019s disease: improving clinical outcomes. Springer, Cham, pp 405\u2013431. https:\/\/doi.org\/10.1007\/978-3-031-32815-2_17"},{"key":"1499_CR176","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/B978-0-323-85654-6.00042-3","volume-title":"Neurobiology of brain disorders","author":"MP Parsons","year":"2023","unstructured":"Parsons MP, Raymond LA (2023) Huntington disease. Neurobiology of brain disorders. Elsevier, Amsterdam, pp 275\u2013292. https:\/\/doi.org\/10.1016\/B978-0-323-85654-6.00042-3"},{"issue":"5","key":"1499_CR177","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1212\/wnl.45.5.951","volume":"45","author":"JS Paulsen","year":"1995","unstructured":"Paulsen JS, Butters N, Sadek JR, Johnson SA, Salmon DP, Swerdlow NR, Swenson MR (1995) Distinct cognitive profiles of cortical and subcortical dementia in advanced illness. Neurology 45(5):951\u2013956. https:\/\/doi.org\/10.1212\/wnl.45.5.951","journal-title":"Neurology"},{"issue":"3","key":"1499_CR178","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1136\/jnnp.71.3.310","volume":"71","author":"JS Paulsen","year":"2001","unstructured":"Paulsen JS, Ready RE, Hamilton JM, Mega MS, Cummings JL (2001) Neuropsychiatric aspects of Huntington\u2019s disease. J Neurol Neurosurg Psychiatry 71(3):310\u2013314. https:\/\/doi.org\/10.1136\/jnnp.71.3.310","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"1499_CR179","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1002\/mds.23402","volume":"26","author":"MS Pe\u00f1a","year":"2011","unstructured":"Pe\u00f1a MS, Yaltho TC, Jankovic J (2011) Tardive dyskinesia and other movement disorders secondary to aripiprazole. Mov Disord 26(1):147\u2013152. https:\/\/doi.org\/10.1002\/mds.23402","journal-title":"Mov Disord"},{"issue":"6","key":"1499_CR180","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/j.celrep.2018.07.017","volume":"24","author":"K Pircs","year":"2018","unstructured":"Pircs K, Petri R, Madsen S, Bratt\u00e5s PL, Vuono R, Ottosson DR, St-Amour I, Hersbach BA, Matusiak-Br\u00fcckner M, Lundh SH, Peters\u00e9n \u00c5, D\u00e9glon N, H\u00e9bert SS, Parmar M, Barker RA, Jakobsson J (2018) Huntingtin aggregation impairs autophagy, leading to Argonaute-2 accumulation and global MicroRNA dysregulation. Cell Rep 24(6):1397\u20131406. https:\/\/doi.org\/10.1016\/j.celrep.2018.07.017","journal-title":"Cell Rep"},{"issue":"5","key":"1499_CR181","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1038\/mt.2016.12","volume":"24","author":"K Pollock","year":"2016","unstructured":"Pollock K, Dahlenburg H, Nelson H, Fink KD, Cary W, Hendrix K, Annett G, Torrest A, Deng P, Gutierrez J, Nacey C, Pepper K, Kalomoiris S, D Anderson J, McGee J, Gruenloh W, Fury B, Bauer G, Duffy A, Nolta JA (2016) Human mesenchymal stem cells genetically engineered to overexpress brain-derived neurotrophic factor improve outcomes in Huntington\u2019s disease mouse models. Mol Ther 24(5):965\u2013977. https:\/\/doi.org\/10.1038\/mt.2016.12","journal-title":"Mol Ther"},{"issue":"12","key":"1499_CR182","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1002\/mds.22188","volume":"23","author":"J Priller","year":"2008","unstructured":"Priller J, Ecker D, Landwehrmeyer B, Craufurd D (2008) A Europe-wide assessment of current medication choices in Huntington\u2019s disease. Mov Disord 23(12):1788. https:\/\/doi.org\/10.1002\/mds.22188","journal-title":"Mov Disord"},{"issue":"9","key":"1499_CR183","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1002\/mds.25075","volume":"27","author":"T Pringsheim","year":"2012","unstructured":"Pringsheim T, Wiltshire K, Day L, Dykeman J, Steeves T, Jette N (2012) The incidence and prevalence of Huntington\u2019s disease: a systematic review and meta-analysis. Mov Disord 27(9):1083\u20131091. https:\/\/doi.org\/10.1002\/mds.25075","journal-title":"Mov Disord"},{"issue":"8","key":"1499_CR184","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1136\/jnnp.47.8.844","volume":"47","author":"N Quinn","year":"1984","unstructured":"Quinn N, Marsden CD (1984) A double blind trial of sulpiride in Huntington\u2019s disease and tardive dyskinesia. J Neurol Neurosurg Psychiatry 47(8):844\u2013847. https:\/\/doi.org\/10.1136\/jnnp.47.8.844","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4\u20135","key":"1499_CR185","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.brainresbull.2009.07.010","volume":"80","author":"RA Quintanilla","year":"2009","unstructured":"Quintanilla RA, Johnson GVW (2009) Role of mitochondrial dysfunction in the pathogenesis of Huntington\u2019s disease. Brain Res Bull 80(4\u20135):242\u2013247. https:\/\/doi.org\/10.1016\/j.brainresbull.2009.07.010","journal-title":"Brain Res Bull"},{"issue":"10","key":"1499_CR186","doi-asserted-by":"publisher","first-page":"4886","DOI":"10.1007\/s12035-021-02472-0","volume":"58","author":"T Rana","year":"2021","unstructured":"Rana T, Behl T, Sehgal A, Mehta V, Singh S, Bhatia S, Al-Harrasi A, Bungau S (2021) Exploring the role of autophagy dysfunction in neurodegenerative disorders. Mol Neurobiol 58(10):4886\u20134905. https:\/\/doi.org\/10.1007\/s12035-021-02472-0","journal-title":"Mol Neurobiol"},{"issue":"12","key":"1499_CR187","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/S1474-4422(21)00249-0","volume":"20","author":"O Rascol","year":"2021","unstructured":"Rascol O, Fabbri M, Poewe W (2021) Amantadine in the treatment of Parkinson\u2019s disease and other movement disorders. Lancet Neurol 20(12):1048\u20131056. https:\/\/doi.org\/10.1016\/S1474-4422(21)00249-0","journal-title":"Lancet Neurol"},{"issue":"2","key":"1499_CR188","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1159\/000443738","volume":"46","author":"MD Rawlins","year":"2016","unstructured":"Rawlins MD, Wexler NS, Wexler AR, Tabrizi SJ, Douglas I, Evans SJW, Smeeth L (2016) The prevalence of Huntington\u2019s disease. Neuroepidemiology 46(2):144\u2013153. https:\/\/doi.org\/10.1159\/000443738","journal-title":"Neuroepidemiology"},{"key":"1499_CR189","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2018-EHDN.265","author":"R Reilmann","year":"2018","unstructured":"Reilmann R, Gordon MF, Anderson KE, Feigin A, Tabrizi SJ, Leavitt BR, Stout JC, Piccini P, Rynkowski G, Volkinshtein R, Savola J (2018) J05 Legato-hd study: a phase 2 study assessing the efficacy and safety of laquinimod as a treatment for Huntington disease. Clin Ther. https:\/\/doi.org\/10.1136\/jnnp-2018-EHDN.265","journal-title":"Clin Ther"},{"key":"1499_CR190","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.94.15_supplement.4531","author":"R Reilmann","year":"2020","unstructured":"Reilmann R, Ross C, Testa C, Frank S, Evers M, De Haan M, Valles-Sanchez A, Konstantinova P, Van Deventer S, Higgins J (2020) Translation of AMT-130 preclinical data to inform the design of the first FDA-approved human AAV gene therapy clinical trial in adults with early manifest Huntington\u2019s disease (4531). AAN Enterprises. https:\/\/doi.org\/10.1212\/WNL.94.15_supplement.4531","journal-title":"AAN Enterprises"},{"key":"1499_CR191","doi-asserted-by":"publisher","unstructured":"ReilmannR, Gordon MF, Anderson KE, Feigin A, Tabrizi SJ, Leavitt BR, Stout JC, Piccini P, Borowsky B, Rynkowski G (2019) The efficacy and safety results of laquinimod as a treatment for Huntington disease. In: AAN Enterprises. LEGATO-HD.https:\/\/doi.org\/10.1212\/WNL.92.15_supplement.S16.007","DOI":"10.1212\/WNL.92.15_supplement.S16.007"},{"key":"1499_CR192","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/B978-0-12-381328-2.00014-6","volume":"98","author":"A Reiner","year":"2011","unstructured":"Reiner A, Dragatsis I, Dietrich P (2011) Genetics and neuropathology of Huntington\u2019s disease. Int Rev Neurobiol 98:325\u2013372. https:\/\/doi.org\/10.1016\/B978-0-12-381328-2.00014-6","journal-title":"Int Rev Neurobiol"},{"issue":"2","key":"1499_CR193","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1177\/026988119601000213","volume":"10","author":"MA Reveley","year":"1996","unstructured":"Reveley MA, Dursun SM, Andrews H (1996) A comparative trial use of sulpiride and risperidone in Huntington\u2019s disease: a pilot study. J Psychopharmacol 10(2):162\u2013165. https:\/\/doi.org\/10.1177\/026988119601000213","journal-title":"J Psychopharmacol"},{"key":"1499_CR194","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.freeradbiomed.2014.06.023","volume":"74","author":"M Ribeiro","year":"2014","unstructured":"Ribeiro M, Rosenstock TR, Oliveira AM, Oliveira CR, Rego AC (2014) Insulin and IGF-1 improve mitochondrial function in a PI-3K\/Akt-dependent manner and reduce mitochondrial generation of reactive oxygen species in Huntington\u2019s disease knock-in striatal cells. Free Radical Biol Med 74:129\u2013144. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2014.06.023","journal-title":"Free Radical Biol Med"},{"issue":"1","key":"1499_CR195","doi-asserted-by":"publisher","first-page":"31","DOI":"10.2217\/nmt-2018-0040","volume":"9","author":"A Richard","year":"2019","unstructured":"Richard A, Frank S (2019) Deutetrabenazine in the treatment of Huntington\u2019s disease. Neurodegener Dis Manag 9(1):31\u201337. https:\/\/doi.org\/10.2217\/nmt-2018-0040","journal-title":"Neurodegener Dis Manag"},{"issue":"1","key":"1499_CR196","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3233\/JHD-189001","volume":"7","author":"FB Rodrigues","year":"2018","unstructured":"Rodrigues FB, Wild EJ (2018) Huntington\u2019s disease clinical trials corner: February 2018. J Huntington\u2019s Dis 7(1):89\u201398. https:\/\/doi.org\/10.3233\/JHD-189001","journal-title":"J Huntington\u2019s Dis"},{"key":"1499_CR197","doi-asserted-by":"publisher","DOI":"10.31157\/an.v1iinpress.346","author":"A Rodr\u00edguez","year":"2022","unstructured":"Rodr\u00edguez A, Morales E, Herrera C, Monta\u00f1o L, Mart\u00ednez K, Meza M, Del Villar N, Mendoza X (2022) Current knowledge and future directions in Huntington\u2019s disease. Arch Neurosci. https:\/\/doi.org\/10.31157\/an.v1iinpress.346","journal-title":"Arch Neurosci"},{"issue":"4","key":"1499_CR198","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.ymthe.2005.05.006","volume":"12","author":"E Rodriguez-Lebron","year":"2005","unstructured":"Rodriguez-Lebron E, Denovan-Wright EM, Nash K, Lewin AS, Mandel RJ (2005) Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6\/1 Huntington\u2019s disease transgenic mice. Mol Ther 12(4):618\u2013633. https:\/\/doi.org\/10.1016\/j.ymthe.2005.05.006","journal-title":"Mol Ther"},{"key":"1499_CR302","doi-asserted-by":"publisher","unstructured":"Roos RA  (2010) Huntington's disease: a clinical review. Orphanet J Rare Dis 5:40. https:\/\/doi.org\/10.1186\/1750-1172-5-40","DOI":"10.1186\/1750-1172-5-40"},{"issue":"2","key":"1499_CR199","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1002\/1531-8257(199903)14:2<326::aid-mds1019>3.0.co;2-q","volume":"14","author":"HD Rosas","year":"1999","unstructured":"Rosas HD, Koroshetz WJ, Jenkins BG, Chen YI, Hayden DL, Beal MF, Cudkowicz ME (1999) Riluzole therapy in Huntington\u2019s disease (HD). Mov Disord 14(2):326\u2013330. https:\/\/doi.org\/10.1002\/1531-8257(199903)14:2%3c326::aid-mds1019%3e3.0.co;2-q","journal-title":"Mov Disord"},{"key":"1499_CR200","volume-title":"A Physician\u2019s guide to the management of Huntington\u2019s disease","author":"A Rosenblatt","year":"1999","unstructured":"Rosenblatt A, Ranen NG, Nance MA, Paulsen JS (1999) A Physician\u2019s guide to the management of Huntington\u2019s disease. Huntington\u2019s Disease Society of America, Arlington"},{"issue":"10","key":"1499_CR201","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.2174\/1389450111007011218","volume":"11","author":"T Rosenstock","year":"2010","unstructured":"Rosenstock T, Duarte A, Rego C (2010) Mitochondrial-associated metabolic changes and neurodegeneration in Huntington\u2019s disease-from clinical features to the bench. Curr Drug Targets 11(10):1218\u20131236","journal-title":"Curr Drug Targets"},{"issue":"5","key":"1499_CR202","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.neuint.2011.04.009","volume":"59","author":"TR Rosenstock","year":"2011","unstructured":"Rosenstock TR, de Brito OM, Lombardi V, Louros S, Ribeiro M, Almeida S, Ferreira IL, Oliveira CR, Rego AC (2011) FK506 ameliorates cell death features in Huntington\u2019s disease striatal cell models. Neurochem Int 59(5):600\u2013609. https:\/\/doi.org\/10.1016\/j.neuint.2011.04.009","journal-title":"Neurochem Int"},{"issue":"6","key":"1499_CR203","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1046\/j.1468-1331.2002.00447_4.x","volume":"9","author":"U Rot","year":"2002","unstructured":"Rot U, Kobal J, Sever A, Pirtosek Z, Mesec A (2002) Rivastigmine in the treatment of Huntington\u2019s disease. European J Neurol 9(6):689\u2013690. https:\/\/doi.org\/10.1046\/j.1468-1331.2002.00447_4.x","journal-title":"European J Neurol"},{"issue":"3","key":"1499_CR204","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/s0301-0082(02)00016-3","volume":"67","author":"PP Roux","year":"2002","unstructured":"Roux PP, Barker PA (2002) Neurotrophin signaling through the p75 neurotrophin receptor. Prog Neurobiol 67(3):203\u2013233. https:\/\/doi.org\/10.1016\/s0301-0082(02)00016-3","journal-title":"Prog Neurobiol"},{"issue":"3","key":"1499_CR205","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/ncb3101","volume":"17","author":"Y-N Rui","year":"2015","unstructured":"Rui Y-N, Xu Z, Patel B, Chen Z, Chen D, Tito A, David G, Sun Y, Stimming EF, Bellen HJ, Cuervo AM, Zhang S (2015) Huntingtin functions as a scaffold for selective macroautophagy. Nat Cell Biol 17(3):262\u2013275. https:\/\/doi.org\/10.1038\/ncb3101","journal-title":"Nat Cell Biol"},{"key":"1499_CR206","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s42466-023-00285-1","volume":"5","author":"C Saft","year":"2023","unstructured":"Saft C, Burgunder J-M, Dose M, Jung HH, Katzenschlager R, Priller J, Nguyen HP, Reetz K, Reilmann R, Seppi K (2023) Symptomatic treatment options for Huntington\u2019s disease (guidelines of the German Neurological Society). Neurol Res Pract 5:61. https:\/\/doi.org\/10.1186\/s42466-023-00285-1","journal-title":"Neurol Res Pract"},{"key":"1499_CR207","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1212\/wnl.41.1.156","volume":"41","author":"M Sajatouic","year":"1991","unstructured":"Sajatouic M, Verbanac P, Ramirez LF, Meltzer HY (1991) Clozapine treatment of psychiatric symptoms resistant to neuroleptic treatment in patients with Huntington\u2019s chorea. Neurology 41:156\u2013156. https:\/\/doi.org\/10.1212\/wnl.41.1.156","journal-title":"Neurology"},{"key":"1499_CR208","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1002\/mds.26021","volume":"29","author":"C Sampaio","year":"2014","unstructured":"Sampaio C, Borowsky B, Reilmann R (2014) Clinical trials in Huntington\u2019s disease: interventions in early clinical development and newer methodological approaches. Mov Disord 29:1419\u20131428. https:\/\/doi.org\/10.1002\/mds.26021","journal-title":"Mov Disord"},{"key":"1499_CR209","doi-asserted-by":"publisher","first-page":"4604","DOI":"10.1073\/pnas.96.8.4604","volume":"96","author":"E Scherzinger","year":"1999","unstructured":"Scherzinger E, Sittler A, Schweiger K, Heiser V, Lurz R, Hasenbank R, Bates GP, Lehrach H, Wanker EE (1999) Self-assembly of polyglutamine-containing huntingtin fragments into amyloid-like fibrils: implications for Huntington\u2019s disease pathology. Proc Natl Acad Sci 96:4604\u20134609","journal-title":"Proc Natl Acad Sci"},{"key":"1499_CR210","unstructured":"Schobel SA, (2021). Preliminary results from generation HD1, a phase III trial of tominersen in individuals with manifest HD. CHDI 16th annual HD therapeutics conference."},{"key":"1499_CR211","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1177\/070674370404900617","volume":"49","author":"DP Seitz","year":"2004","unstructured":"Seitz DP, Millson RC (2004) Quetiapine in the management of psychosis secondary to Huntington\u2019s disease: a case report. Canadian J Psychiatry 49:413\u2013413. https:\/\/doi.org\/10.1177\/070674370404900617","journal-title":"Canadian J Psychiatry"},{"key":"1499_CR212","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1002\/ana.20207","volume":"56","author":"H Seo","year":"2004","unstructured":"Seo H, Sonntag KC, Isacson O (2004) Generalized brain and skin proteasome inhibition in Huntington\u2019s disease. Ann Neurol 56:319\u2013328. https:\/\/doi.org\/10.1002\/ana.20207","journal-title":"Ann Neurol"},{"key":"1499_CR213","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1007\/s004150170071","volume":"248","author":"K Seppi","year":"2001","unstructured":"Seppi K, Mueller J, Bodner T, Brandauer E, Benke T, Weirich-Schwaiger H, Poewe W, Wenning GK (2001) Riluzole in Huntington\u2019s disease (HD): an open label study with one year follow up. J Neurol 248:866\u2013869. https:\/\/doi.org\/10.1007\/s004150170071","journal-title":"J Neurol"},{"key":"1499_CR214","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s40263-019-00695-3","volume":"34","author":"KM Shannon","year":"2020","unstructured":"Shannon KM (2020) Recent advances in the treatment of Huntington\u2019s disease: targeting DNA and RNA. CNS Drugs 34:219\u2013228","journal-title":"CNS Drugs"},{"issue":"14","key":"1499_CR215","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.2174\/1389450122666210224105945","volume":"22","author":"A Sharma","year":"2021","unstructured":"Sharma A, Behl T, Sharma L, Aelya L, Bungau S (2021) Mitochondrial dysfunction in Huntington\u2019s disease: pathogenesis and therapeutic opportunities. Curr Drug Targets 22(14):1637\u20131667. https:\/\/doi.org\/10.2174\/1389450122666210224105945","journal-title":"Curr Drug Targets"},{"key":"1499_CR216","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/0896-6273(95)90345-3","volume":"14","author":"AH Sharp","year":"1995","unstructured":"Sharp AH, Loev SJ, Schilling G, Li S-H, Li X-J, Bao J, Wagster MV, Kotzuk JA, Steiner JP, Lo A (1995) Widespread expression of Huntington\u2019s disease gene (IT15) protein product. Neuron 14:1065\u20131074. https:\/\/doi.org\/10.1016\/0896-6273(95)90345-3","journal-title":"Neuron"},{"key":"1499_CR217","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1093\/nar\/gkx1239","volume":"46","author":"X Shen","year":"2018","unstructured":"Shen X, Corey DR (2018) Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs. Nucleic Acids Res 46:1584\u20131600. https:\/\/doi.org\/10.1093\/nar\/gkx1239","journal-title":"Nucleic Acids Res"},{"key":"1499_CR218","doi-asserted-by":"publisher","first-page":"4566","DOI":"10.1093\/hmg\/ddw286","volume":"25","author":"JW Shin","year":"2016","unstructured":"Shin JW, Kim K-H, Chao MJ, Atwal RS, Gillis T, Macdonald ME, Gusella JF, Lee J-M (2016) Permanent inactivation of Huntington\u2019s disease mutation by personalized allele-specific CRISPR\/Cas9. Hum Mol Genet 25:4566\u20134576. https:\/\/doi.org\/10.1093\/hmg\/ddw286","journal-title":"Hum Mol Genet"},{"key":"1499_CR219","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.141042","author":"JW Shin","year":"2022","unstructured":"Shin JW, Hong EP, Park SS, Choi DE, Seong IS, Whittaker MN, Kleinstiver BP, Chen RZ, Lee J-M (2022) Allele-specific silencing of the gain-of-function mutation in Huntington\u2019s disease using CRISPR\/Cas9. JCI Insight. https:\/\/doi.org\/10.1172\/jci.insight.141042","journal-title":"JCI Insight"},{"key":"1499_CR220","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1007\/s40265-014-0231-7","volume":"74","author":"M Shirley","year":"2014","unstructured":"Shirley M, Perry CM (2014) Aripiprazole (ABILIFY MAINTENA\u00ae): a review of its use as maintenance treatment for adult patients with schizophrenia. Drugs 74:1097\u20131110. https:\/\/doi.org\/10.1007\/s40265-014-0231-7","journal-title":"Drugs"},{"key":"1499_CR221","doi-asserted-by":"publisher","first-page":"eaar3959","DOI":"10.1126\/scitranslmed.aar3959","volume":"10","author":"AL Southwell","year":"2018","unstructured":"Southwell AL, Kordasiewicz HB, Langbehn D, Skotte NH, Parsons MP, Villanueva EB, Caron NS, \u00d8stergaard ME, Anderson LM, Xie Y (2018) Huntingtin suppression restores cognitive function in a mouse model of Huntington\u2019s disease. Sci Trans Med 10:eaar3959. https:\/\/doi.org\/10.1126\/scitranslmed.aar3959","journal-title":"Sci Trans Med"},{"key":"1499_CR222","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.3390\/biomedicines11082275","volume":"11","author":"A Speidell","year":"2023","unstructured":"Speidell A, Bin Abid N, Yano H (2023) Brain-derived neurotrophic factor dysregulation as an essential pathological feature in Huntington\u2019s disease: mechanisms and potential therapeutics. Biomedicines 11:2275. https:\/\/doi.org\/10.3390\/biomedicines11082275","journal-title":"Biomedicines"},{"key":"1499_CR223","first-page":"69","volume":"14","author":"F Squitieri","year":"2001","unstructured":"Squitieri F, Cannella M, Porcellini A, Brusa L, Simonelli M, Ruggieri S (2001) Short-term effects of olanzapine in Huntington disease. Cogn Behav Neurol 14:69\u201372","journal-title":"Cogn Behav Neurol"},{"key":"1499_CR224","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1007\/s00259-009-1103-3","volume":"36","author":"F Squitieri","year":"2009","unstructured":"Squitieri F, Orobello S, Cannella M, Martino T, Romanelli P, Giovacchini G, Frati L, Mansi L, Ciarmiello A (2009) Riluzole protects Huntington disease patients from brain glucose hypometabolism and grey matter volume loss and increases production of neurotrophins. Eur J Nucl Med Mol Imaging 36:1113\u20131120. https:\/\/doi.org\/10.1007\/s00259-009-1103-3","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1499_CR225","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.ncl.2020.01.010","volume":"38","author":"CM Stahl","year":"2020","unstructured":"Stahl CM, Feigin A (2020) Medical, surgical, and genetic treatment of Huntington disease. Neurol Clin 38:367\u2013378. https:\/\/doi.org\/10.1016\/j.ncl.2020.01.010","journal-title":"Neurol Clin"},{"key":"1499_CR226","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/S1474-4422(23)00127-8","volume":"22","author":"EF Stimming","year":"2023","unstructured":"Stimming EF, Claassen DO, Kayson E, Goldstein J, Mehanna R, Zhang H, Liang GS, Haubenberger D, Adams J, Beck C (2023) Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington\u2019s disease (KINECT-HD): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Neurol 22:494\u2013504. https:\/\/doi.org\/10.1016\/S1474-4422(23)00127-8","journal-title":"Lancet Neurol"},{"issue":"1","key":"1499_CR227","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1136\/practneurol-2021-003074","volume":"22","author":"TB Stoker","year":"2022","unstructured":"Stoker TB, Mason SL, Greenland JC, Holden ST, Santini H, Barker RA (2022) Huntington\u2019s disease: diagnosis and management. Pract Neurol 22(1):32\u201341. https:\/\/doi.org\/10.1136\/practneurol-2021-003074","journal-title":"Pract Neurol"},{"key":"1499_CR228","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1177\/0891988710383573","volume":"23","author":"A Sturrock","year":"2010","unstructured":"Sturrock A, Leavitt BR (2010) The clinical and genetic features of Huntington disease. J Geriatr Psychiatry Neurol 23:243\u2013259. https:\/\/doi.org\/10.1177\/0891988710383573","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"1499_CR229","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1111\/j.1349-7006.2001.tb01077.x","volume":"92","author":"T Sugimoto","year":"2001","unstructured":"Sugimoto T, Kuroda H, Horii Y, Moritake H, Tanaka T, Hattori S (2001) Signal transduction pathways through TRK-A and TRK-B receptors in human neuroblastoma cells. Jpn J Cancer Res 92:152\u2013160. https:\/\/doi.org\/10.1111\/j.1349-7006.2001.tb01077.x","journal-title":"Jpn J Cancer Res"},{"key":"1499_CR230","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/1531-8249(199901)45","volume":"45","author":"S Tabrizi","year":"1999","unstructured":"Tabrizi S, Cleeter M, Xuereb J, Taanman JW, Cooper J, Schapira A (1999) Biochemical abnormalities and excitotoxicity in Huntington\u2019s disease brain. Ann Neurol 45:25\u201332. https:\/\/doi.org\/10.1002\/1531-8249(199901)45","journal-title":"Ann Neurol"},{"key":"1499_CR231","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.neuron.2019.01.039","volume":"101","author":"SJ Tabrizi","year":"2019","unstructured":"Tabrizi SJ, Ghosh R, Leavitt BR (2019) Huntingtin lowering strategies for disease modification in Huntington\u2019s disease. Neuron 101:801\u2013819. https:\/\/doi.org\/10.1016\/j.neuron.2019.01.039","journal-title":"Neuron"},{"key":"1499_CR232","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/s41582-020-0389-4","volume":"16","author":"SJ Tabrizi","year":"2020","unstructured":"Tabrizi SJ, Flower MD, Ross CA, Wild EJ (2020) Huntington disease: new insights into molecular pathogenesis and therapeutic opportunities. Nat Rev Neurol 16:529\u2013546. https:\/\/doi.org\/10.1038\/s41582-020-0389-4","journal-title":"Nat Rev Neurol"},{"key":"1499_CR233","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1089\/ars.2009.2598","volume":"12","author":"A Terman","year":"2010","unstructured":"Terman A, Kurz T, Navratil M, Arriaga EA, Brunk UT (2010) Mitochondrial turnover and aging of long-lived postmitotic cells: the mitochondrial\u2013lysosomal axis theory of aging. Antioxid Redox Signal 12:503\u2013535. https:\/\/doi.org\/10.1089\/ars.2009.2598","journal-title":"Antioxid Redox Signal"},{"key":"1499_CR234","doi-asserted-by":"publisher","DOI":"10.1016\/B978-012369509-3.50019-6","author":"SV Todi","year":"2007","unstructured":"Todi SV, Williams AJ, Paulson HL (2007) Polyglutamine disorders including huntington\u2019s disease. Mol Neurol. https:\/\/doi.org\/10.1016\/B978-012369509-3.50019-6","journal-title":"Mol Neurol"},{"key":"1499_CR235","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2023.106291","volume":"187","author":"H Tong","year":"2023","unstructured":"Tong H, Yang T, Liu L, Li C, Sun Y, Jia Q, Qin Y, Chen L, Zhao X, Zhou G, Yan S, Li XJ, Li S (2023) Aberrant splicing of mutant huntingtin in Huntington\u2019s disease knock-in pigs. Neurobiol Dis 187:106291. https:\/\/doi.org\/10.1016\/j.nbd.2023.106291","journal-title":"Neurobiol Dis"},{"key":"1499_CR236","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25073845","author":"H Tong","year":"2024","unstructured":"Tong H, Yang T, Xu S, Li X, Liu L, Zhou G, Li. (2024) Huntington\u2019s disease: complex pathogenesis and therapeutic strategies. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms25073845","journal-title":"Int J Mol Sci"},{"key":"1499_CR237","doi-asserted-by":"publisher","first-page":"157","DOI":"10.3233\/JHD-170245","volume":"6","author":"AM Travessa","year":"2017","unstructured":"Travessa AM, Rodrigues FB, Mestre TA, Ferreira JJ (2017) Fifteen years of clinical trials in Huntington\u2019s disease: a very low clinical drug development success rate. J Huntington\u2019s Dis 6:157\u2013163. https:\/\/doi.org\/10.3233\/JHD-170245","journal-title":"J Huntington\u2019s Dis"},{"key":"1499_CR238","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24054310","author":"LM Valor","year":"2023","unstructured":"Valor LM (2023) Molecular research on Huntington\u2019s disease. MDPI. https:\/\/doi.org\/10.3390\/ijms24054310","journal-title":"MDPI"},{"issue":"11","key":"1499_CR239","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.3390\/ph16111513","volume":"16","author":"HJ Van de Roovaart","year":"2023","unstructured":"Van de Roovaart HJ, Nguyen N, Veenstra TD (2023ba) Huntington\u2019s Disease Drug Development: A Phase 3 Pipeline Analysis. Pharmaceuticals 16(11):1513. https:\/\/doi.org\/10.3390\/ph16111513","journal-title":"Pharmaceuticals"},{"issue":"11","key":"1499_CR240","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.3390\/ph16111513","volume":"16","author":"HJ Van de Roovaart","year":"2023","unstructured":"Van de Roovaart HJ, Nguyen N, Veenstra TD (2023b) Huntington\u2019s Disease Drug Development: A Phase 3 Pipeline Analysis. Pharmaceuticals (basel) 16(11):1513. https:\/\/doi.org\/10.3390\/ph16111513","journal-title":"Pharmaceuticals (basel)"},{"key":"1499_CR241","doi-asserted-by":"publisher","DOI":"10.2147\/BTT.S270657","author":"ML van der Bent","year":"2022","unstructured":"van der Bent ML, Evers MM, Vall\u00e8s A (2022) Emerging therapies for Huntington\u2019s disease-Focus on N-terminal Huntingtin and Huntingtin exon 1. Biologics. https:\/\/doi.org\/10.2147\/BTT.S270657","journal-title":"Biologics"},{"key":"1499_CR242","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1176\/jnp.2007.19.4.441","volume":"19","author":"E Van Duijn","year":"2007","unstructured":"Van Duijn E, Kingma E, Van Der Mast R (2007) Psychopathology in verified Huntington\u2019s disease gene carriers. J Neuropsychiatry Clin Neurosci 19:441\u2013448. https:\/\/doi.org\/10.1176\/jnp.2007.19.4.441","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"1499_CR243","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1136\/jnnp.63.1.35","volume":"63","author":"J Van Vugt","year":"1997","unstructured":"Van Vugt J, Siesling S, Vergeer M, Van Der Velde E, Roos R (1997a) Clozapine versus placebo in Huntington\u2019s disease: a double blind randomised comparative study. J Neurol Neurosurg Psychiatry 63:35\u201339. https:\/\/doi.org\/10.1136\/jnnp.63.1.35","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1499_CR244","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1007\/s11940-013-0219-8","volume":"15","author":"A Videnovic","year":"2013","unstructured":"Videnovic A (2013) Treatment of huntington disease. Curr Treat Options Neurol 15:424\u2013438. https:\/\/doi.org\/10.1007\/s11940-013-0219-8","journal-title":"Curr Treat Options Neurol"},{"key":"1499_CR245","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.neuint.2016.11.003","volume":"101","author":"C Vidoni","year":"2016","unstructured":"Vidoni C, Castiglioni A, Seca C, Secomandi E, Melone MA, Isidoro C (2016) Dopamine exacerbates mutant Huntingtin toxicity via oxidative-mediated inhibition of autophagy in SH-SY5Y neuroblastoma cells: beneficial effects of anti-oxidant therapeutics. Neurochem Int 101:132\u2013143. https:\/\/doi.org\/10.1016\/j.neuint.2016.11.003","journal-title":"Neurochem Int"},{"key":"1499_CR246","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/S0140-6736(07)60111-1","volume":"369","author":"FO Walker","year":"2007","unstructured":"Walker FO (2007) Huntington\u2019s disease. The Lancet 369:218\u2013228. https:\/\/doi.org\/10.1016\/S0140-6736(07)60111-1","journal-title":"The Lancet"},{"key":"1499_CR247","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.ajhg.2009.02.003","volume":"84","author":"SC Warby","year":"2009","unstructured":"Warby SC, Montpetit A, Hayden AR, Carroll JB, Butland SL, Visscher H, Collins JA, Semaka A, Hudson TJ, Hayden MR (2009) CAG expansion in the Huntington disease gene is associated with a specific and targetable predisposing Haplogroup. Am J Hum Genet 84:351\u2013366. https:\/\/doi.org\/10.1016\/j.ajhg.2009.02.003","journal-title":"Am J Hum Genet"},{"key":"1499_CR248","unstructured":"Watkins RE. News Releases News Releases."},{"key":"1499_CR249","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s13311-013-0180-y","volume":"10","author":"CC Weihl","year":"2013","unstructured":"Weihl CC (2013) Monitoring autophagy in the treatment of protein aggregate diseases: steps toward identifying autophagic biomarkers. Neurotherapeutics 10:383\u2013390. https:\/\/doi.org\/10.1007\/s13311-013-0180-y","journal-title":"Neurotherapeutics"},{"key":"1499_CR250","doi-asserted-by":"publisher","first-page":"7862","DOI":"10.1523\/JNEUROSCI.22-18-07862.2002","volume":"22","author":"CL Wellington","year":"2002","unstructured":"Wellington CL, Ellerby LM, Gutekunst C-A, Rogers D, Warby S, Graham RK, Loubser O, Van Raamsdonk J, Yang Y-Z, Gafni J (2002) Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington\u2019s disease. J Neurosci 22:7862\u20137872. https:\/\/doi.org\/10.1523\/JNEUROSCI.22-18-07862.2002","journal-title":"J Neurosci"},{"key":"1499_CR251","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/B978-0-444-64074-1.00047-1","volume":"157","author":"P Weydt","year":"2018","unstructured":"Weydt P, Dupuis L, Petersen \u00c5 (2018) Thermoregulatory disorders in Huntington disease. Handb Clin Neurol 157:761\u2013775. https:\/\/doi.org\/10.1016\/B978-0-444-64074-1.00047-1","journal-title":"Handb Clin Neurol"},{"issue":"3","key":"1499_CR252","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1080\/14728214.2021.1962285","volume":"26","author":"R Wiggins","year":"2021","unstructured":"Wiggins R, Feigin A (2021) Emerging therapeutics in Huntington\u2019s disease. Exp Opin Emerg Drugs 26(3):295\u2013302. https:\/\/doi.org\/10.1080\/14728214.2021.1962285","journal-title":"Exp Opin Emerg Drugs"},{"key":"1499_CR253","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/S1474-4422(17)30280-6","volume":"16","author":"EJ Wild","year":"2017","unstructured":"Wild EJ, Tabrizi SJ (2017) Therapies targeting DNA and RNA in Huntington\u2019s disease. Lancet Neurol 16:837\u2013847. https:\/\/doi.org\/10.1016\/S1474-4422(17)30280-6","journal-title":"Lancet Neurol"},{"issue":"2","key":"1499_CR254","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1002\/pnp.750","volume":"26","author":"B Wildridge","year":"2022","unstructured":"Wildridge B, Rozewicz S, Mohamed A, James J, Connolly G (2022) Use of clozapine for psychosis and chorea in Huntington\u2019s disease systematic narrative review. Prog Neurol Psychiatry 26(2):38\u201343","journal-title":"Prog Neurol Psychiatry"},{"key":"1499_CR255","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/S0140-6736(96)03181-9","volume":"348","author":"J Wokke","year":"1996","unstructured":"Wokke J (1996) Riluzole. The Lancet 348:795\u2013799. https:\/\/doi.org\/10.1016\/S0140-6736(96)03181-9","journal-title":"The Lancet"},{"key":"1499_CR256","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41582-023-00832-z","volume":"19","author":"H Wood","year":"2023","unstructured":"Wood H (2023) A new drug to treat chorea in Huntington disease. Nat Rev Neurol 19:387. https:\/\/doi.org\/10.1038\/s41582-023-00832-z","journal-title":"Nat Rev Neurol"},{"key":"1499_CR257","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1093\/abbs\/gmw044","volume":"48","author":"Y Wu","year":"2016","unstructured":"Wu Y, Lu J, Kang T (2016) Human single-stranded DNA binding proteins: guardians of genome stability. Acta Biochim Biophys Sin 48:671\u2013677. https:\/\/doi.org\/10.1093\/abbs\/gmw044","journal-title":"Acta Biochim Biophys Sin"},{"key":"1499_CR258","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11910-017-0739-9","volume":"17","author":"KJ Wyant","year":"2017","unstructured":"Wyant KJ, Ridder AJ, Dayalu P (2017) Huntington\u2019s disease\u2014update on treatments. Curr Neurol Neurosci Rep 17:1\u201311. https:\/\/doi.org\/10.1007\/s11910-017-0739-9","journal-title":"Curr Neurol Neurosci Rep"},{"key":"1499_CR259","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.stemcr.2017.01.022","volume":"8","author":"X Xu","year":"2017","unstructured":"Xu X, Tay Y, Sim B, Yoon S-I, Huang Y, Ooi J, Utami KH, Ziaei A, Ng B, Radulescu C (2017) Reversal of phenotypic abnormalities by CRISPR\/Cas9-mediated gene correction in Huntington disease patient-derived induced pluripotent stem cells. Stem Cell Reports 8:619\u2013633. https:\/\/doi.org\/10.1016\/j.stemcr.2017.01.022","journal-title":"Stem Cell Reports"},{"key":"1499_CR260","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S0092-8674(00)80623-6","volume":"101","author":"A Yamamoto","year":"2000","unstructured":"Yamamoto A, Lucas JJ, Hen R (2000) Reversal of neuropathology and motor dysfunction in a conditional model of Huntington\u2019s disease. Cell 101:57\u201366. https:\/\/doi.org\/10.1016\/S0092-8674(00)80623-6","journal-title":"Cell"},{"key":"1499_CR261","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1172\/JCI92087","volume":"127","author":"S Yang","year":"2017","unstructured":"Yang S, Chang R, Yang H, Zhao T, Hong Y, Kong HE, Sun X, Qin Z, Jin P, Li S (2017) CRISPR\/Cas9-mediated gene editing ameliorates neurotoxicity in mouse model of Huntington\u2019s disease. J Clin Investig 127:2719\u20132724. https:\/\/doi.org\/10.1172\/JCI92087","journal-title":"J Clin Investig"},{"issue":"1","key":"1499_CR262","doi-asserted-by":"publisher","first-page":"5989","DOI":"10.1038\/s41467-020-19873-9","volume":"11","author":"H Yang","year":"2020","unstructured":"Yang H, Yang S, Jing L, Huang L, Chen L, Zhao X, Yang W, Pan Y, Yin P, Qin ZS, Tang B, Li S, Li X-J (2020) Author Correction: Truncation of mutant huntingtin in knock-in mice demonstrates exon1 huntingtin is a key pathogenic form. Nat Commun 11(1):5989. https:\/\/doi.org\/10.1038\/s41467-020-19873-9","journal-title":"Nat Commun"},{"issue":"113718","key":"1499_CR263","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2021.113718","volume":"224","author":"Y Yang","year":"2021","unstructured":"Yang Y, Yu D, Zhu X, Du G, Wang W, Zou F, Wang H, Zhang R, Ye L, Tian J (2021) Synthesis and analysis of dihydrotetrabenazine derivatives as novel vesicular monoamine transporter 2 inhibitors. Eur J Med Chem 224(113718):113718. https:\/\/doi.org\/10.1016\/j.ejmech.2021.113718","journal-title":"Eur J Med Chem"},{"key":"1499_CR264","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41573-023-00762-x","volume":"16","author":"H Yin","year":"2017","unstructured":"Yin H, Kauffman KJ, Anderson DG (2017) Delivery technologies for genome editing. Nat Rev Drug Discov 16:387\u2013399. https:\/\/doi.org\/10.1038\/s41573-023-00762-x","journal-title":"Nat Rev Drug Discov"},{"key":"1499_CR265","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2023.114767","author":"SA Zadegan","year":"2023","unstructured":"Zadegan SA, Kupcha L, Patino J, Rocha NP, Teixeira AL, Stimming EF (2023) Obsessive-compulsive and perseverative behaviors in Huntington\u2019s disease. Behav Brain Res. https:\/\/doi.org\/10.1016\/j.bbr.2023.114767","journal-title":"Behav Brain Res"},{"key":"1499_CR266","doi-asserted-by":"publisher","DOI":"10.1176\/appi.neuropsych.20230120","author":"SA Zadegan","year":"2024","unstructured":"Zadegan SA, Ramirez F, Reddy KS, Sahin O, Rocha NP, Teixeira AL, Furr SE (2024) Treatment of depression in Huntington\u2019s disease: a systematic review. J Neuropsychiatry Clin Neurosci. https:\/\/doi.org\/10.1176\/appi.neuropsych.20230120","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"1499_CR267","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1126\/science.1059581","volume":"293","author":"C Zuccato","year":"2001","unstructured":"Zuccato C, Ciammola A, Rigamonti D, Leavitt BR, Goffredo D, Conti L, Macdonald ME, Friedlander RM, Silani V, Hayden MR (2001) Loss of huntingtin-mediated BDNF gene transcription in Huntington\u2019s disease. Science 293:493\u2013498. https:\/\/doi.org\/10.1126\/science.1059581","journal-title":"Science"}],"container-title":["Archives of Pharmacal Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12272-024-01499-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12272-024-01499-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12272-024-01499-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T14:07:49Z","timestamp":1719842869000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12272-024-01499-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,19]]},"references-count":270,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["1499"],"URL":"https:\/\/doi.org\/10.1007\/s12272-024-01499-w","relation":{},"ISSN":["0253-6269","1976-3786"],"issn-type":[{"value":"0253-6269","type":"print"},{"value":"1976-3786","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,19]]},"assertion":[{"value":"18 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}